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Abstract 
Development of  a Multi-Functional Construct for Central Nervous System Repair 
Mihir S. Shanbhag 
Margaret A. Wheatley, PhD 
 
 Engineered tissue strategies for central nervous system (CNS) repair have the 
potential for localizing treatment using a wide variety of cells and/or growth factors.  
However, these strategies are often limited by their ability to address only one aspect of 
the injury.  Here we report the development of an alginate construct that acts as a multi-
functional tissue scaffold for CNS repair, and as a localized growth factor delivery 
vehicle.  Initially the effect of alginate constructs on the model mouse neuroblastoma 
(NB2a) cell line was studied.  NB2a attachment and differentiation patterns were 
observed on the surface of alginate constructs.  These results were then used in order to 
demonstrate the ability of these constructs to support neural progenitor cell (NPC) 
attachment, preserve viability, and initiate lineage differentiation of cultured NPCs. Three 
different hydrogel constructs were evaluated and it was found that alginate optimally 
supported NPC attachment and viability.  In addition, a laminin-111 surface coating of 
alginate enhanced NPC attachment and migration.  It was also demonstrated that 
encapsulation of fibroblasts over expressing mitogens (NT-3 or BDNF) promoted unique 
NPC differentiation profiles while directing the phenotypical lineage of the cells. 
Moreover, the encapsulation of these growth factor producing fibroblasts within the 
alginate construct reduced the severity of injury when implanted in vivo.  A final test of 
the construct showed that alginate constructs seeded with NPCs allowed for migration 
and integration of lineage restricted cells into the surrounding injured tissue, while 
directing phenotypical differentiation and influencing the injury environment.    
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1. Introduction 
 
1.1 Central Nervous System (CNS) Injury and Treatments 
 
 Central nervous system injury is classified as any trauma to the brain or spinal 
cord that disrupts communication between neurons.  It is a devastating occurrence and 
there is currently no complete cure [1-4].   However, many treatments have focused on 
alleviating the symptoms.   
 Traumatic brain injury (TBI) affects nearly 5.3 million Americans, and there are 
around 1.5 million new cases reported yearly [6].  Transportation accidents involving 
automobiles and bicycles cause a large amount (~50%) of all TBIs and the largest portion 
of TBI in people under age 75. For those aged 75 and older, falls cause the majority of 
TBIs.   Approximately 20% of TBIs are due to violence such as firearms and child abuse, 
with about 3% due to sport injuries [9,10].  More recently, TBI is a frequent injury 
apparent in individuals associated with war zones. TBI has been identified as the 
"signature injury" among wounded soldiers of the current military engagement in 
Afghanistan and Iraq [8,11]. Symptoms of a TBI can be mild, moderate, or severe and are 
directly correlated to the extent of the damage to the brain.   A person with a mild TBI 
may remain conscious or may experience a loss of consciousness for a few seconds or 
minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, 
dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue 
or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with 
memory, and concentration [4-7,9,11].  A person with a moderate or severe TBI may 
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show these same symptoms, but may also have a headache that gets worse or does not go 
away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from 
sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in 
the extremities, loss of coordination, and increased confusion, restlessness, or agitation.  
Extremely severe cases may result in permanent disability or even death [1]. 
 Spinal cord injury (SCI) affects nearly 400,000 people in the United States, while 
approximately 11,000 people sustain new spinal injuries every year [3]. Most SCI’s are 
incurred as a result of auto accidents, sports injuries, falls or industrial accidents [1-3,15]. 
Nearly 60% of those affected are 30 years or younger and are mostly men. Following 
spinal cord injury there is disruption of communication between the brain and other parts 
of the body, and messages are no longer transmitted across the injured area. SCI can 
occur at any level and the bodily functions that may be lost or altered depend on the level 
of injury. The higher the injury in the spinal cord, the more movement and sensation that 
is affected. An injury at the cervical level may cause paralysis of both arms and legs 
resulting in quadriplegia, while lower injuries like those at the thoracic level may affect 
only the lower part of the body causing paraplegia. Injuries are also classified as 
complete or incomplete depending on whether there is total or partial loss of sensation 
and movement below the level of injury [1,3]. In extremely severe conditions, SCI can 
also result in total paralysis or even death.  
 CNS neurons (brain or spinal cord) are extremely fragile and survive following an 
injury due to their poor intrinsic regenerative ability of the neurons themselves, presence 
of a glial scar and circulating macrophages and proteoglycans, and a lack of adequate 
neurotrophic factors [15,16]. Various strategies have been employed to aid in neuronal 
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regeneration following injury.  These include peripheral biomaterial implants to replace 
lost tissue, stem cell treatments, and providing neurotrophic factors [16-19,23,24]. While 
these strategies have shown positive results individually, a treatment method needs to be 
developed that combines many of the above mentioned strategies to obtained the desired 
results.   Here we will attempt to combine neurotrophic factor therapy with neural 
stem/progenitor cell transplants using a biomaterial matrix for delivery.    
1.2 Neurotrophic Factor Therapy 
 
Neurotrophic factors, such as nerve growth factor (NGF), brain derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), and 
neurotrophin-5 (NT-5) are a family of proteins that are an essential part of neuronal 
development and survival [16,17,97]. They belong to a class of growth factors, which are 
capable of signaling neuronal cells to survive, differentiate, and proliferate. Neurotrophic 
factors are secreted by a target tissue and act by preventing the associated neurons from 
initiating apoptosis, thus allowing the neurons to survive [19,41-44]. More recently 
neurotrophic factors have also been shown to induce differentiation of neural stem cells 
to form neurons [41-44].  Hence, a great deal of research has focused on delivering these 
growth factors to the sites of CNS injury.   
 Neurotrophic factors act by attaching to receptors on the tips of neurons and on 
the cell body. The signal produced by the growth factor can then be carried through the 
axon of the neuronal cell.  Thus far, several neurotrophic factor receptors have been 
discovered.  These receptors may also be potential targets for therapy. A specific receptor 
called tyrosine kinase receptors (trk) is required for the action of neurotrophic factors 
[45,46]. Trks are high affinity and specific receptors for neurotrophic factors.  TrkB 
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seems to be a receptor for brain-derived neurotrophic factor and trkC for neurotrophin-3 
[16,17,97]. Additionally, all neurotrophins can bind to p75 which is a low affinity 
neurotrophic factor receptor. It is a member of the tumor necrosis super family [19,41-
46]. 
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor which was 
originally found in the brain, but is also present throughout the CNS. It is a protein which 
affects neurons of the central and peripheral nervous system and is one the main 
neurotrophic factors used in this study.   Similarly, Neurotrophin-3 (NT-3) has the same 
types of functions as BDNF [41-46].  Research has shown that these two neurotrophic 
factors help to support the survival of existing neurons, and encourage the growth and 
differentiation of new neurons and synapses through axonal and dendritic sprouting.  
A major obstacle in the use of neurotrophic factors is that they must be repeatedly 
administered locally and multiple invasive techniques would have to be employed in 
order to administer them.  A major solution is the use of genetically engineered 
fibroblasts that continually produce these neurotrophic factors [47-52]. When implanted 
however, these allogeneic fibroblasts cause an immune response and are rejected by the 
host.  Hence, the use of biomaterial delivery agents has come to light as a possible 
solution.   
1.3 Neural Stem/Progenitor Cell Treatments 
 
 Embryonic stem cells are another extremely promising avenue for CNS 
regeneration and are classified as extremely immature, undifferentiated cells that have 
unlimited self- renewal capacity and pluripotent differentiation properties [55-58]. These 
cells can give rise to any tissue within the body.  However, as an embryonic stem cell is 
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given the right cues and time to mature, it becomes more specialized and eventually 
forms into a neural stem cell (NSC) while maintaining its unlimited ability to self-renew 
[55-57]. As the neural stem cell matures throughout development it eventually loses its 
capacity for self-renewal and is called a neural progenitor cell (NPC).  Isolating pure 
populations of stem or progenitor cells is extremely difficult and most studies have 
worked with using mixed populations [55-58].  These are grown as colonies and referred 
to as neurospheres.  CNS stem/.progenitor cells have the ability to generate only neurons, 
oligodendrocytes, and astrocytes, hence giving them trilineage ability.  With these three 
phenotypes, neural stem/progenitor cells can replace all types of CNS cells.  Hence, stem 
cell therapies for CNS repair have a great deal of interest due to their potential for curing 
the devastating effects of CNS injury through direct cell replacement and differentiation 
[55-58]. Additionally, stem/progenitor cell transplants have the ability to be accepted by 
the host’s immune system without the need for immune suppression.  This is due their 
extremely immature nature and undifferentiated state [55-58].  
 Multipotent stem/progenitor cells seem very promising for regenerative medicine 
and have been shown to integrate with host cells when directly transplanted to the site of 
injury [34].   However, direct implantation of undifferentiated stem/progenitor cells have 
been shown to cause tumors while contributing to the glial scar through astrocytic 
differentiation [.  Here we will attempt to deliver these  cells through a biomaterial matrix 
in conjunction with neurotrophic factors while minimizing the risks and accessing the 
benefits associated with these cells.   
1.4 Alginate 
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 Since the main goal of this study was to combine the previously described 
neurotrophic factor therapy with neural stem cell treatment, a biopolymer delivery agent 
needed to be chosen and studied.  One such delivery agent is alginate.  Alginate is an 
extremely favorable polysaccharide, with promising cell delivery and tissue engineering 
properties, obtained from brown seaweed. It contains β-(1-4)-linked D-mannuronic acid 
(M) and α-(1-4)-linked L-guluronic acid (G) residues [67,69,70].  It can be characterized 
as a linear and unbranched chain.   Due to the L-guluronic acid groups, alginate has the 
ability to form gels with divalent cations like calcium, magnesium, and barium, and 
certain trivalent cations like iron and aluminium [69,70]. The properties of the gel are 
governed by the sequence and composition of the monomer chains.  Due to its ease in 
manipulation and favorable characteristics, alginate was used as the biopolymer of choice 
in this study. 
 Alginate hydrogels can be prepared by a method of “fast gelling” where a solution 
of sodium alginate is added to a cation solution (i.e. calcium chloride) which causes an 
immediate cross-linking.   Alternatively, alginate hydrogels can be prepared through a 
method of “slow gelling”, where the cation (i.e. calcium sulfate or calcium carbonate) is 
added to the sodium alginate and therefore allows the hydrogel to slowly gel through a 
gradual release of cations due to the low initial solubility of the calcium solution. This in 
turn allows the solution to be poured into a “mold” in order order to generate the desired 
geometrical shape [71-75].  Alginate belongs to a group of compounds that are generally 
regarded as safe  (GRAS) by the FDA. It has also been used in tissue engineering for cell 
encapsulation, spinal implants as well as cell and gene delivery [50, 65].    
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 An extremely important characteristic of alginate hydrogels is that they can be 
coated with polycations such as poly-L-ornithine (PLO), which acts as a semipermeable 
membrane on the surface of the hydrogel. Thus this coating can prevent the immune cells 
of the host from affecting the alginate hydrogel, when it is implanted in vivo,  while 
allowing beneficial smaller molecular weight species to pass across [52,71-75].  Since, 
the goal of this study was to create a multi-functional alginate construct that contains 
encapsulated cells that produce neurotrphic factors, this PLO coating protects them while 
allowing the diffusion of the neurotrophic factors released from the cells. Thus immune 
suppression of the host and its complications can be avoided. Additionally, alginate can 
also be modified with specific polypeptides (i.e. laminin) that would further make the 
surface of the hydrogel favorable as a tissue engineering construct for NPC adhesion and 
differentiation [54].   
1.5 Statement of the Problem 
 
 The main goal of this study is to create a novel, tailor-made alginate construct that 
acts as a multi-functional, tissue engineering graft for CNS repair.  In order to accomplish 
this, the graft will employ NPCs, in conjunction with a localized growth factor delivery 
vehicle consisting of encapsulated neurotrophic factor producing fibroblasts (Fb/BDNF, 
Fb/NT-3). Since the construct will act as a NPC scaffold, it will be designed to be a stable 
and growth permissive substrate for neuronal cell adhesion, differentiation, and 
proliferation for integration into the site of injury.  This will be accomplished through the 
promotion of neural tissue genesis as well as by repairing damaged cells. Additionally, 
the construct will have a perm-selective membrane for control of neurotrophic factor 
release, and exclusion of components of the immune system in order to ensure proper 
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growth factor delivery.  With these conditions being met, the construct should ultimately 
function as a graft for the regeneration of injured neurons and as a guide for axons in 
order to promote proper CNS recovery.  Moreover, the construct should also be non-toxic 
and suitable for human transplant while at the same time avoiding any immunogenic 
complications. Finally, the creation of the construct should be reproducible and have the 
correct physiology in order to ensure proper recovery treatment for CNS injury. The 
specific aims of this study are as follows:  
 
1. Fabrication of a tailor made alginate construct that is stable and can be implanted at 
the site of CNS injury.   
a. The construct should not contain toxic substances, be easily moldable, and should 
promote the proliferation and differentiation of neuronal cells and help in bridging 
the gap in a CNS lesion.  
b. The construct should viably encapsulate genetically modified fibroblasts. 
c. Should result in the creation of a neurotrophic factor delivery vehicle that can also 
act as a neural tissue engineered scaffold.   
2. To evaluate the behavior of NPCs in conjunction with different alginate constructs  
a. To show the differentiation and regenerative potential of NPCs on alginate 
constructs with and without encapsulated neurotrophic factor producing 
fibroblasts.  
i. Examine the effect of a fragment of laminin vs the entire laminin 
peptide on NPC attachment and differentiation. 
ii. Observe attachment of NPCs to different alginate constructs 
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iii. Determine NPC viability after attachment and differentiation on the 
construct.   
iv. Study the migration of differentiated neural progenitor cells on the 
surface of alginate constructs.  
b. Examine the role of the microenvironment on NPC behavior. 
i. Determine if NPCs have developed receptors for neurotrophic 
factors 
ii. Determine multi-lineage capability of neural progenitor cells on 
different alginate constructs. 
iii. Evaluate the phenotypical morphology of differentiated neural 
progenitor cells on the surface of different alginate constructs. 
3. Development of a working model of the novel construct, which can be tested for its 
neural recovery potential through the implantation in the brain and spinal cord of an 
injured, non-immune, suppressed rodent. 
.     
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2. Background 
 
2.1 CNS Injury  
 
 Central nervous system injury (CNS) is a devastating occurrence and is classified 
as any trauma to the brain and/or spinal cord causing loss of movement and sensation, 
memory loss, speech problems, the inability to concentrate, and behavioral problems [2, 
3]. CNS damage initiates a series of cellular and molecular events that evolve over 
several days[4-7]. The main cell types involved in these changes are astrocytes, 
microglia, and oligodendrocyte precursors, with some involvement of meningeal cells 
and stem cells that contribute to a growth inhibitory glial scar. The first cells to arrive in a 
CNS injury are macrophages from the bloodstream and microglia migrating from the 
surrounding tissue.  These cells begin their processes within hours of injury [1-5]. After 
3–5 days, large numbers of oligodendrocyte precursors are recruited from the 
surrounding tissue, and if the injury penetrates the meninges, meningeal cells will migrate 
to cover the exposed CNS surface. The final cellular structure of the glial scar is 
predominantly astrocytic, and these cells divide and slowly migrate into CNS injuries, 
eventually to fill the vacant space. The consequence is that after the initial period of cell 
death and damage, during which neuroprotective and glioprotective treatments are the 
main therapeutic strategy, any form of treatment designed to repair CNS damage will 
have to take place in a glial scar environment. 
 
2.1.1 Traumatic Brain Injury  
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 TBI occurs when a sudden trauma causes damage to the brain. TBI occurs when 
the head suddenly and violently hits an object, or when an object pierces the skull and 
enters brain tissue [6-8].  Symptoms of TBI can be mild, moderate, or severe, depending 
on the extent of the damage to the brain. [6, 9, 10].   
 Immediately after a brain injury, a primary damage mechanism begins.  Primary 
brain damage includes shearing of white-matter tracts, focal contusions, haematomas 
(intracerebral and extracerebral), and diffuse swelling. At the cellular level, early 
neurotrauma events, which can occur minutes to hours after initial injury, include 
microporation of membranes, leaky ion channels, and stearic conformational changes in 
proteins. At higher shear rates, blood vessels can be torn, causing haemorrhages [6, 7, 9, 
11].  Importantly, different head injuries seem to initiate different secondary injury 
mechanisms that may occur a long time after the primary damage.  These mechanisms 
determine the extent of secondary brain damage. Secondary processes develop over hours 
and days, and include neurotransmitter release, free-radical generation, calcium-mediated 
damage, gene activation, mitochondrial dysfunction, and inflammatory responses [6, 7, 9, 
11]. 
 As a response to trauma the brain releases neurotransmitters at a high rate.  This 
release seems to exacerbat`1qe ion-channel leakage, worsen astrocytic swelling, and 
contribute to brain swelling. Neurotransmitter release continues for many days after TBI 
in human beings, with calcium-mediated damage being a major cause of early necrotic 
cell death [7, 11].  
 Inflammatory response is an important component of TBI, particularly around 
contusions and haemorrhages. The maximum response occurs within a few days, but 
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cytokines are released from microglia, astrocytes, and polymorphonuclear cells within 
hours after TBI, leading to opening of the blood–brain barrier, complement-mediated 
activation of cell death, and the triggering of apoptosis.  Additionally, apoptosis may be 
caused by mitochondrial dysfunction after TBI [12, 13]. This can cause energy failure, 
with a decrease in production of ATP and consumption of oxygen by 40–50%. Hence, it 
can trigger the opening of the mitochondrial transition pore, setting off an autodestruct 
phenomenon that induces both apoptosis and necrosis. Mitochondrial dysfunction might 
also lead to axonal disruption [7, 13].  Therefore a repair mechanism that can stimulate 
regeneration in spite of these secondary injuries needs to be addressed.   
2.1.2 Spinal Cord Injury (SCI) 
 
  Spinal cord injury (SCI) is initiated through a sudden, traumatic blow to the spine 
that fractures or dislocates vertebrae. The damage to the cord begins at the moment of 
injury when displaced bone fragments, disc material, or ligaments bruise or tear into 
spinal cord tissue. Most injuries to the spinal cord don't completely sever it, but rather 
cause fracture and compression of the vertebrae, which then crush and destroy the axons 
[1, 5]. An injury to the spinal cord can damage many or almost all of these axons. Some 
injuries will allow almost complete recovery. Others will result in complete paralysis. 
  Spinal cord injury can be classified as two different types: complete or 
incomplete.  In a complete injury, there is no function below the "neurological" level, 
defined as the lowest level that has intact neurological function. If a person has some 
level below which there is no motor and sensory function, the injury is said to be 
complete. Recent evidence suggests that less than 5% of people with complete spinal 
cord injury recover locomotion [3].  A person with an incomplete injury retains some 
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sensation or movement below the level of the injury. The lowest spinal cord level is S4-5, 
representing the anal sphincter and peri-anal sensation. Recent evidence suggest that over 
95% of people with "incomplete" spinal cord injury recover some locomotory ability.  
 Following SCI there is axonal injury leading to death of damaged neuronal cells 
and vascular damage leading to hypoxia. The inflammatory response following injury 
leads to the appearance of macrophages at the injury site which in turn contribute to the 
glial scar formation. The scar formation by the macrophages, astrocytes and microglia is 
a result of the body re-establishing the blood brain barrier thereby preventing further 
injury to the CNS [1, 14]. The cells and connective tissue that make up the scar have been 
found to release both growth promoting and inhibiting molecules. Regeneration of central 
nervous system neurons basically depends on the severity of the injury to the neurons. If 
the somata of the neurons are involved in the injury, then the nervous system cells die. If 
the injury is only a transection or severing of an axon, without injury to the soma the cells 
would die by apoptosis days or weeks after the injury. Once the distal nerve segments are 
separated from their cell bodies they start to degrade and are degraded by macrophages. 
Degeneration of the axon causes loss of contact with the surrounding astrocytes and 
oligodendrocytes leading to loss of functions that are dependent on the activity of the 
neurons [15]. To combat this, the neurons try to grow into the lesion but this process is 
abrupt and there are no lengthy neuronal processes that bridge the lesion. This is due to 
the retraction of the growth cones when they come in contact with the injury and also due 
to myelin removal. 
 Earlier it was believed that CNS neurons lacked the ability to regenerate. Recent 
research has shown that the CNS neurons do have the ability to regenerate, but the ability 
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of the neurons to regenerate, bridge the lesion and regain their functionality depends on 
various factors [15]. The rate of regeneration not only varies between different CNS 
neurons but also within different branches of the same neuron. Supply of neurotrophic 
factors plays a vital role in neuronal regeneration. Following CNS neuronal injury the 
presence of neurotrophic factors is insufficient, but they are essential for the survival of 
the axotomized neurons [16, 17]. The percentage of surviving axotomized neurons is 
reduced by about 50% within the first 7 days, if there is not enough circulating BDNF. 
Experiments performed by Giehl et al have demonstrated that infusion of BDNF directly 
into the cortex can help to save these axotomized neurons showing that there is a lack of 
endogenous trophic factors for the axotomized corticospinal neurons [18-20]. Therefore 
BDNF along with other neurotrophic factors plays a vital role in neuronal regeneration.  
Additionally, repair mechanisms need to be studied that can help in bridging a gap in a 
spinal cord injury.   
2.2 CNS Repair Strategies 
 
 Currently, there are no complete cures for traumatic CNS injury.  Accomplishing 
regrowth and reconnection of damaged neural cells is the major goal of research in CNS 
repair. A significant amount of research for traumatic CNS injury has been focused on 
influencing the environment of the injury in order to promote axonal regeneration [14, 
21, 22].  Hence, recent advances have incorporated strategies to increase the effects of 
positive molecules while limiting the effects of the negative molecules at the site of 
injury.  These advances have resulted in a decrease in the extent of damage at the time of 
the injury, but there have been very few advances in initiating regeneration of damaged 
tissue. Various strategies have been used to treat spinal cord injuries and several different 
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approaches are also currently being tested. Some of the strategies include grafting of 
peripheral nerves to the lesion, providing growth factors, stem cell transplants, decreasing 
growth inhibiting molecules, and use of biomaterials. Some of these strategies are 
discussed below. 
2.2.1 Cell Grafting 
 
 An important and successful strategy for CNS repair has been the use of cell 
transplantation to regenerate neuronal cells.  Neuronal cells in the peripheral nervous 
system (PNS) are similar to those in the CNS, in that they regenerate only if their cell 
bodies are intact after injury, but they differ in their regenerative capacity if they remain 
in tact [23, 24].  
 Shortly after neural injury the body of the cell swells and is followed by Wallerian 
degeneration where the distal portion of the axons and myelin sheath start to degrade. 
Finally, the intact neurolemma cells divide and regeneration tubes are formed through 
which new axons and eventually myelin reform [14, 23-26]. Axotomized neurons start to 
express growth associated proteins like GAP-43, cytokines and other neuropeptides. 
Schwann cells, whose primary function in the peripheral nervous system is myelination 
of axons, begin expressing cell adhesion molecules and extracellular matrix proteins that 
aid in neural cell regeneration [27]. Since Schwann cells act as guidance channels for 
regenerating axons in the PNS they were transplanted in the CNS to test their 
effectiveness. Trials with injections of cultured Schwann cells or grafts containing 
Schwann cells in injured spinal cord have shown an increase in neural regeneration. 
Additionally, when Schwann cells were transplanted immediately following spinal injury 
  
16 
they had a higher survival rate and axons were seen growing into the guidance channels. 
However, only 1% of the regenerated axons were found to enter the host tissue [27-29]. 
 Olfactory neurons are the only kind of neurons that are produced and continue to 
divide throughout adult life. The olfactory ensheathing cells (OECs) are specialized glial 
cells that encourage the growth of axons from the mucosa and they possess the 
characteristics of both Schwann cells and astrocytes [29-32]. Unlike the Schwann cells 
that are confined to the PNS these OECs accompany the olfactory axons to the CNS and 
provide guidance for the axons to their correct positions in the olfactory glomerulus. 
These are the only glial cells that have the capacity to cross the PNS-CNS boundary and 
can also myelinate axons in vitro. It was found that grafting of the olfactory ensheathing 
cells resulted in axons growing through the lesion, and continued to regenerate through 
the injury region [30-32]. The olfactory cells also caused the myelination of both 
individual as well as groups of axons. The advantage of this type of treatment is that the 
cells from patient’s own olfactory mucosa could be cultured, thereby avoiding the 
problems of graft rejection and immune suppression. The limiting factor of this kind of 
therapy for CNS repair is that the graft would not be readily available following injury. 
2.2.2 Reducing Growth Inhibitory Molecules 
 
 Following injury oligodendrocytes and astrocytes are present as a result of the 
inflammatory response and create a glial scar. Both these cell types have growth 
inhibitory molecules for axons and axons can only regenerate if they either have no 
receptors to these inhibitory molecules or if they can bypass the signals released from 
them [33-35]. 
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 Growth inhibitory proteins present at the glial scar near an injury site are a major 
barrier for axon growth. Reactive astrocytes that form the glial scar express many 
different types of chondroitin sulfate proteoglycans (CSPG). The full complement of 
proteoglycans expressed at the glial scar, and their time course of expression, has not 
been confirmed. However, in culture, reactive astrocytes block axon growth and express 
inhibitory proteoglycans [33-35]. Other cell types also have been shown to contribute to 
scar formation. These include meningeal cells that express growth inhibitory proteins on 
their cell surfaces and invade the scar region. Oligodendrocyte precursor cells proliferate 
after CNS demyelinating injury and express the NG2 proteoglycan that is known to 
inhibit neurite growth. Ultimately, astrocytes produce the previously described 
proteoglycans that inhibit neuronal regeneration by blocking the growth promoting 
characteristics of laminin and neurotrophic factors. An enzyme that has been shown to be 
efficient against the proteoglycan mediated inhibition is bacterial Chondroitinase ABC. 
This enzyme acts by cleaving the glycosaminoglycan (GAG) side chains on the 
chondroitin sulfate proteoglycans (CSPGs) [36-38]. This enzyme however does not fully 
digest the GAG chains leaving behind side chains which, even though they are less 
inhibitory than entire GAG chains, reduce the axonal regeneration capacity.  
Additionally, chondroitinase ABC has been found to be extremely unstable.  As a final 
effect, chondroitinase ABC administration has been shown to reduce the unfavorable 
environment created by the CNS injury [37-39]. Combining neurotrophic factors and 
stem cells with a stable form of this enzyme could possibly enhance axonal regeneration. 
2.2.3 Neurotrophic Factor Treatments 
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As previously described, immediately following a major CNS injury, cells from 
the immune system migrate to the site of trauma causing additional damage to nerve cells 
that may have initially survived the injury.  This phenomenon causes axons to lose their 
myelination and impairs the conduction of action potentials.  Because of this the 
remaining tissue is rendered useless.  The nervous system is further degraded because of 
the retraction of severed axons which cut off any connection between the brain and 
corresponding muscles in the body.  Within hours the thick glial scar tissue is formed at 
the site of injury as a natural response by the body[1].  This scar acts as a mechanical 
barrier against the delivery of neurotrophic factors and inhibits any possible nerve 
regeneration.  
Neurotrophic factors an essential part of neuronal development and survival.  
They are produced mainly in the embryonic stage in humans, to aid in the growth and 
development of CNS. These growth factors are not generally produced during adult life 
unless there is an injury to the nervous system [17, 39-42].  Studies using neurotrophic 
factors to treat adult spinal cord injury have shown that they not only help to prevent 
atrophy of neurons but also to help in their regeneration [43, 44].   
Neurotrophic factors act by attaching to receptors on the tips, or nerve terminals, and on 
the cell body. The signal produced by the growth factor can then be carried through the 
axon of the neuronal cell.  Thus far, several neurotrophic factor receptors have been 
discovered.  These receptors may also be potential targets for therapy. A specific receptor 
called tyrosine kinase (trk) is required for the action of neurotrophic factors. Trks have 
been defined as high affinity and are specific receptors for neurotrophic factors.  TrkB 
seems to be a receptor for brain-derived neurotrophic factor and trkC for NT-3.  
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Additionally, all neurotrophins can bind to p75 which is a low affinity neurotrophic factor 
receptor. It is a member of the tumor necrosis super family [17]. 
BDNF is a neurotrophic factor which was originally found in the brain, but is also 
present in the periphery. It is a protein which has activity on neurons of the central and 
peripheral nervous system and on the main neurotrophic factors used in this study.   
Similarly, NT-3 has the same types of functions as BDNF.  Research has shown that 
these two neurotrophic factors help to support the survival of existing neurons, and 
encourage the growth and differentiation of new neurons and synapses through axonal 
and dendritic formation [18].  
Even though neurotrophic factors have such an important function in neuronal 
survival and regeneration, a major obstacle to the use of neurotrophic factors is that these 
growth factors must be administered locally and repeated invasive techniques would have 
to be employed in order to administer them.  A major solution is the use of genetically 
engineered fibroblasts that continually produce these neurotrophic factors.   
 Transplanting cells that have been genetically engineering to release neurotrophic 
factors at the site of the trauma is another approach to the treatment of CNS injury. 
Studies have shown that implantation of primary rat fibroblasts, modified to express NGF 
and BDNF, into adult rats with CNS injury led to survival and regeneration of neurons 
[45-50]. Transplantation of fibroblasts that express NT-3 in adult rats with dorsal cord 
lesion led to partial functional recovery. These genetically engineered cells have also 
been found to promote neuronal regeneration when transplanted months after injury 
which proves that they induce existing neurons to extend neurites into the lesion [41, 44]. 
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 While the transplantation of genetically modified cells is promising, they pose the 
risk of immune response and long-term immuno-suppressive therapy is required.  A 
possible solution to this problem has been to encapsulate the cells in a selectively 
permeable graft that would allow for the diffusion of growth factors and waste out of the 
graft and cell nutrients into it while acting as a barrier to immune cells.  Success has been 
shown using materials such as collagen, acrylonitrile-vinyl chloride and polyethersulfone 
hollow fibers to encapsulate genetically engineered Schwann cells and fibroblasts that 
produce neurotrophins and then transplanting them at the site of injury [14, 27, 45, 51].   
Another possible way to encapsulate these cells is to use the biopolymer alginate since it 
provides a stable, perm-selective barrier for encapsulation when coated with poly-L-
ornithine and is non-toxic within the body [52].  
2.2.4 Neural Stem/Progenitor Cells 
 
 Embryonic stem cells (ESCs) are extremely immature cells found in the inner 
mass of cells in the blastocytic stage (4-5 days post fertilization).  These ESCs are 
classified as pluripotent and can differentiate into all three primary germ layers: 
ectoderm, endoderm, and mesoderm.  This allows them to give rise to every tissue within 
the body [55-58].  Additionally ESCs have an unlimited self-renewal ability and when no 
differentiation stimuli are given can maintain their undifferentiated form.  This in turn 
leads to a virtually unlimited source of cells.  Due, to their extreme promise and capacity 
for differentiation. ESC therapy for regenerative medicine has a great deal of interest due 
to the potential for curing the devastating effects of loss of tissue.  However, ethical 
issues cloud stem cell research due to the destruction of the embryo during studies.  
  
21 
Additionally, because of their highly undifferentiated nature and proliferative capacity, 
direct injection of ESCs has shown to form tumors [95,96]. 
 An embryonic stem cell that continues through development and forms the 
ectoderm, eventually becomes more mature and gives rise to neural stem cells (NSCs) 
(Fig 2.1).  These are multi-potent cells that have the ability to self-renew while generating 
the main phenotypical cells of the CNS [55-58].  NSCs have the ability to generate 
neurons, oligodendrocytes, and astrocytes, hence giving them trilineage ability (Fig 2.1).   
Research has shown that when the neural plate first develops, it contains an extremely 
large amount of neural stem cells.  These multipotent stem cells seem very promising and 
have been shown to integrate with host cells when directly transplanted to the site of 
spinal cord injury [34].  However, like ESCs, NSCs are extremely proliferative and have 
the ability to form tumors when injected into the body [95,96].   
 Once the NSC continues to mature, it eventually loses it unlimited self-renewal 
capacity.  These mature stem cells are then called neural progenitor cells (NPCs) and 
must be continually replenished after terminal differentiation.  NPCs are defined as 
specialized neural cells that are derived from immature NSCs [55-58,60].  Since, they are 
much more mature than NSCs, they are sometimes referred to as “adult stem cells”. 
NPCs give rise to the same types of cells as NSCs (neurons, astrocytes, and 
oligodendrocytes). Unlike ESCs or NSCs, NPCs have targeting receptors and can move 
towards the body tissues where they are needed, since they are more mature.  However, 
isolating pure populations of NSCs or NPCs is extremely difficult and studies have 
focused on using mixed populations [55-58,60]. Like its predecessors, NPCs still 
  
22 
maintain their volatile proliferative capacity with the risk of tumor formation when 
injected to injury sites [95,96].   
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Illustration showing the developmental process of embryonic stem 
cells towards a terminal neural lineage 
Figure 2.1: Multi-Lineage Differentiation of Neural Stem Cells 
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In culture, NPCs grow in suspension as spherical aggregates or colonies called 
neurospheres.  These neurospheres contain NSCs that are normally present in very small 
numbers as well as a large amount of NPCs that are restricted in their proliferative and 
phenotypic potentials and are derived from stem cells [53-56].  Plating neurospheres on 
adhesive substrates, such as laminin and poly-D-Lysine, induces phenotypic 
differentiation into neurons, astrocytes, and oligodendrocytes as well as migration of cells 
out of the neurosphere.  Studies have shown that transplanting neurospheres to spinal 
cord injury models provides cells with favorable conditions, which facilitate cell survival, 
proliferation and differentiation [53-56]. 
 The goal in neural stem cell transplant therapy is to provide adequate numbers of 
cells to appropriate sites for useful cellular replacement.  In principle, three types of 
therapies have been considered.  One straightforward therapeutic approach has focused 
on using dissociated cells for replacement.  In this approach, either purified or mixed 
populations of stem cells have been used and transplanted at the site of CNS injury.  The 
second therapeutic approach has been to develop devices that are a combination of 
biomaterials and cells. These devices are then developed and implanted at the sites of 
injury.  The third and final approach has used stem cells and precursor cells to generate 
mature neural cells in culture.  These synthetic CNS cells can then be transplanted.  Each 
of these approaches has been met with moderate success, with the second approach 
having the greatest potential for advancement [14, 22, 25, 36-38, 57, 58].   
 In addition to the risk of tumor formation, a major obstacle to stem/progenitor cell 
treatments however is the fact that undifferentiated transplanted cells seem to contribute 
to the glial scar by taking on an astrocytic phenotype.  This is mainly due to the 
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inflammatory and inhospitable environmental cues that have been generated due to the 
injury[14, 59, 60].  Hence, a great deal of research has focused on changing the 
environmental cues given to the stem cells before and after delivery.    
 This thesis is based on the hypothesis that the potential of stem cells can be 
maximized by development of a scaffold that protects and localizes the activity of these 
stem cells.  The study is focused on the creation of a novel, growth-permissive and 
adhesive substrate for the stem and progenitor cells, while providing a constant supply of 
growth factors essential for their survival.  This will help in regeneration of damaged 
tissue as well as the formation of new neural tissue.  Additionally, this study will focus on 
studying the cues related to stem cell differentiation and the effect of these cues when 
implanted at the site of injury.   
2.2.5 Biomaterials and Tissue Engineering/Regenerative Medicine 
 
 Tissue engineering and regenerative medicine are extremely promising 
approaches for the regeneration of damaged or lost neural cells in the CNS.  New 
strategies provide an opportunity to create and deliver new tissue at a specific site [14, 
22, 51, 61-63].  This is mainly done through the development of a biomaterial scaffold 
containing different cells that can be implanted into the area requiring treatment.  The 
early successes of neural tissue engineering have used grafts seeded with Schwann cells.  
These cells, whose primary function is the myelination of axons in the PNS, have been 
shown to express cell adhesion molecules and extracellular matrix proteins that aid in 
axonal regeneration.  Trials with grafts containing Schwann cells in injured spinal cord 
shown axonal regeneration and the promotion of neuronal development in damaged areas 
[27].  More recent advances have used olfactory ensheathing cells.  These cells are 
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specialized glial cells that encourage the growth of axons and are responsible for the 
regeneration of olfactory axons throughout the life of adult mammals.  It was found that 
grafting the olfactory ensheathing cells and implanting them at the site of injury resulted 
in axonal regeneration [22, 56].  Genetically engineered fibroblasts that produce 
neurotrophic factors have also been used for regeneration capabilities [14, 46-50, 57, 64, 
65].  Other research has focused on the use of cell-free biocompatible polymers that act 
as physical bridges at the site of injury.  These cell free bridges have been shown to 
physically control inflammation and scar tissue formation and hence limit the effects of 
negative molecules at the site of injury [51, 61, 62, 66-68].  One such highly favorable 
biomaterial is alginate.   
  
2.3 Alginate 
 
 Alginate is a linear polysaccharide derived from brown seaweed.  It is a water 
soluble copolymer consisting of repeating monomeric units of 1-4 linked α-L-guluronic 
and β-D-mannuronic acid residues. Sodium alginate is a hydrated polyelectrolyte in 
solution and occurs in a ribbon conformation [65, 67, 68].   
 Alginate forms a gel with most divalent cations and the properties of the gel are 
governed by the type of cationic and the sequence and proportion of the monomer units 
in the polymer. Increasing the ratio of α-L-guluronic monomers, increases the strength of 
the gel that is formed.  Alginate gels are very similar to solids in retaining their shape and 
in resisting stress.  The property of alginate to gel in the presence of polycations 
combined with the fact that it is known to be biocompatible and its byproducts are non-
toxic within the body, has made it an extremely popular agent for tissue engineering. 
  
27 
Alginate has been shown to be a favourable agent for drug delivery while enhancing the 
effects of neurotrophic factors and helping in preventing glial scar tissue [51, 63, 65, 67-
69]. Hence, research involving alginate in tissue engineering for cell encapsulation and 
CNS treatment is an extremely promising pursuit. 
2.3.1 Properties of Alginate 
 
 The structure of alginate and the relationship of the chemical structure to its gel-
forming abilities have been widely studied. Alginates are polysaccharides isolated from 
brown seaweed and algae such as Laminaria hyperborea and lessonia.  Alginate has been 
characterized as linear unbranched copolymers that contain homopolymeric blocks of 
(1,4)-linked -D-mannuronic acid (M) and C-5 epimer,-L-guluronic acid (G) residues, 
respectively, which are covalently linked together in different sequences or blocks (Fig 
2.2 A). The blocks are either similar or strictly alternating (MMMMM, GGGGGG, or 
GMGMGM), and the relative amount depends on the origin of the alginate [70, 71].  
Additionally, G blocks have been found to be stiffer than alternating blocks, which in 
turn are more soluble at low pH.  Alginates can be prepared with a wide range of 
molecular weights (MWs, 50-100 000 kDa), and aqueous solutions of alginates have non-
Newtonian characteristics.  The viscosity of an alginate solution depends on the 
concentration of the polymer and the MW distribution. Two G blocks of adjacent 
polymer chains can be cross-linked with multivalent cations (e.g., Ca2+ or Ba2+) through 
interactions with the carboxylic groups in the sugars, which leads to the formation of a 
strong cross-linking [70, 72, 73] (Fig 2.2 B). The overall gel stiffness depends on the 
polymer MW distribution composition and the stoichiometry of the alginate along with 
the cross-linking cation used. In general, the mechanical properties, such as stiffness and 
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swelling, can be controlled by physical factors such as the cross-linking density, cross-
linker type, MW distribution, and chemical modification of the alginate [70, 73]. 
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Figure 2.2: Structural and Cross-Linking Model of Alginate 
Illustration showing the manunroinc and guluronic acid groups of alginate (A.) (from 
ref 116) and crosslinking of alginate with Calcium ions (B.) (from ref 117). 
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 The mass transfer properties of the alginate depend on the appropriate transport of 
gases, nutrients, cells and waste products into and out of the hydrogel. Native alginate gel 
properties such as polymer size and concentration of the cross-linker ion help to 
determine the porous nature of the gel [74]. As a result, the rate of diffusion into and out 
of the alginate gel depends on the size and molecular weight of the particles compared to 
its pores. The diffusion of high molecular weight compounds from alginate hydrogels is 
decreased by an increase in the concentration of alginate or increasing the concentration 
of the cross-linking divalent cations. Additionally, the diffusion of charged molecules 
depends on their interactions with the negatively charged alginate chains [74]. Enhancing 
the delivery of oxygen and nutrients and removal of waste products is essential for 
alginate gels with cells immobilized in them.  
2.3.2 Applications of Alginate 
 
 Alginate gels have numerous and wide-ranging applications. They have 
historically been most widely used in the food industry and been classified by the FDA as 
generally regarded as safe (GRAS).  They have been used as a stabilizer and an 
emulsifier, because of their inherent properties and interactions with proteins, fats, and 
fibers [75-77]. Alginate is also used as a gelling agent for food products, since alginate-
pectin mixtures gel independently of sugar content, and can yield low calorie products.  
Additionally, it has been widely applied in the pharmaceutical industry as an excipient for 
drugs [78], a dental impression material [79], and a wound dressing [80, 81] . As a 
biomaterial, alginate has a number of advantageous features including biocompatibility 
and non-immunogenicity and they are likely related to its hydrophilicity [71-74]. A 
critical advantage is its gentle gelling behavior, which allows encapsulation of various 
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substances with minimal trauma .  Alginate is currently used as a drug delivery vehicle 
for proteins that promote regeneration of neural tissue and as a carrier for transplanted 
cells [50, 65]. Most importantly, alginate seems to have inherent neuronal regenerative 
properties [67-69].  Disadvantages of alginate gels include the fact that they are not 
naturally broken down enzymatically in mammals and hence have poorly regulated 
degradation. In order for the alginate gel to degrade the divalent cation (i.e Ca2+) 
crosslinking it must be pulled away from the alginate gel.  This eventually done through 
the use of PO4-.  In addition, cells do not naturally adhere to alginate [53, 71-74]. 
However, there has been significant research over the past decade to overcome these 
problems and to broaden the utility of alginate hydrogels through the incorporation of 
degradation enzymes, the use of alginates with lower guluronic acid groups for less cross 
linking efficiency, and surface modification of the alginate gels with basement membrane 
polypeptides.   
2.3.3 Alginate for Drug Delivery 
 
 Since alginate hydrogels are easy to make under physiological conditions and 
safe, they have been studied thoroughly for drug delivery and are frequently the material 
of choice for cell encapsulation. Drug release from the hydrogel can be controlled by 
changing the properties of the hydrogel like varying the concentration of alginate used or 
changing the crosslinking ion or coating the gel with a poly cation such as poly-L-
ornithine (PLO).  Most conventional alginate scaffolds are created by introducing the 
alginate to a solution of aqueous calcium chloride or crosslinking it with calcium sulfate.  
These two approaches have been commonly used for drug delivery [73, 82].  However, 
the major disadvantages of this approach are that the gelation kinetics are extremely 
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difficult to control and the resulting scaffold formed from crosslinking is not uniformly 
crosslinked.  
 Alginate hydrogels have been broadly useful for the sustained and localized 
delivery of traditional low molecular weight drugs and macromolecules. The classical 
approach to drug delivery (pills taken orally) leads to high concentrations and poor 
targeting of the drug to the tissue of interest, which can lead to severe side effects, low 
efficiency, and typically does not lead to the sustained presence of the drug [83]. A 
highly localized delivery of small amounts of drug by controlled release from an alginate 
gel in which it is encapsulated is often desirable to allow high local concentrations over 
sustained time periods with minimal tissue exposure at other sites. The release kinetics of 
drugs from alginate gels can be controlled by regulating drug-alginate interactions. When 
there are no chemical interactions between the drug and the polymer, the release depends 
largely on the charge polarization of the molecule [83].  
 In accordance with the previously described drugs, the encapsulation and release 
of proteins from alginate gels can significantly enhance their efficacy and targeting. 
Growth factors can promote or impede cell differentiation, proliferation, tissue growth, 
and vascularization. However, proteins degrade rapidly in the body following injection, 
which forces the administration of very high doses, and potentially causes severe side 
effects. Localized delivery from alginate can potentially ensure sustained local exposure 
over a prolonged time without negative effects [63, 82, 83].  
2.3.4 Alginate for Cell Encapsulation 
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 Another strategy for the use of alginates in biomedical applications is for cell 
encapsulation. This method of repair involves transplanting cells that are protected from 
the host immune system by an artificial, semipermeable membrane.  This  allows for cell 
transplantation without the need for immunosuppression [50, 63]. Additionally, the 
encapsulated cells can be modified to produce therapeutic agents thereby taking 
advantage of the polymer’s drug delivery properties.  Alginate has been proven to meet 
these requirements and has been used extensively for cell encapsulation.  Additionally in 
order to adequately deliver these cells to the desired location and deliver the therapeutic 
agents, the biopoloymer must be degradable.  As previously stated, the rate of release of 
degradation of the alginate matrix encapsulating the cells can be controlled by coating the 
hydrogel with polypeptides such as poly-L-ornithine and poly-L-lysine. These 
polypeptide coatings not only influence the rate of cell and drug release but also make it 
size selective [50, 63].  Hence, the polypeptide coating acts as a barrier against the host 
immune system.   Varying the molecular weight of the polypeptide has been shown to 
permit the release of encapsulated cells thereby avoiding the immune suppressive therapy 
that would be mandatory following foreign cell transplantation. 
 Studies have been conducted where pancreatic islets cells have been encapsulated 
in alginate and transplanted in rats[84]. Following this study various hepatocytes[85], 
stem cells[86] and genetically engineered fibroblasts[50] were used for the delivery of a 
wide range of compounds like hormones, antibodies, and neurotrophic factors. A more 
recent development for the use of alginate hydrogels has been in the area of tissue 
engineering and regenerative medicine.  
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2.3.5 Alginate in Tissue Engineering 
 
 Alginate gels are commonly used as cell delivery vehicles in tissue engineering to 
allow localization of transplanted stem cells and control over their differentiated fate. 
When alginate gels are used for cell transplantation they are usually covalently modified 
to promote cell attachment [22, 51, 63].  This is due to the fact that native alginate does 
not promote significant adhesion since mammalian cells do not have receptors for 
alginate polymers.  This in turn makes alginate gels relatively inert.  Coating of alginate 
gels with laminin has allowed for the scaffold to not only promote cell attachment but 
additionally signal cells and influence their function. Because of this necessary 
modification, the alginate is most commonly used as an encapsulation vehicle for stem 
cells rather than as a growth substrate [63].  Additionally, alginate gels have been used to 
selectively differentiate neural stem cells.  One such important study, by Silva et al. has 
recently shown rapid differentiation of neural stem cells into neurons with 35% of total 
cells staining positive for β-tubulin inside self assembling nanotubes composed of 
IKVAV-containing peptide ampiphiles [87].  Most tissue types consist of more than one 
cell type, whose interactions may be crucial to tissue formation and regeneration, and co-
transplantation of stem and progenitor cells within the scaffold is essential. 
 Alginate has also been used as cell-free bridges for spinal cord repair.  Due to its 
mechanical stability and inherent neural recovery potential, it was found that alginate 
seemed to reduce inflammation and glial scarring at injury site in the rat spinal cord [63, 
67-69].  Due to these findings alginate has been recently used as filler and guidance 
channel in spinal cord transections along with neural stem cells [62].  Additionally, 
scaffolds for tissue engineering are typically designed to degrade at an appropriate rate to 
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allow space for new tissue formation, and control of the degradation kinetics of alginate 
gels can allow one to influence tissue formation [22, 61]. 
2.4 Multi-Functional Construct 
 
 Using the aforementioned therapies for CNS repair, the main goal of this study 
was to create a novel, tailor-made alginate construct that acts as a multi-functional, tissue 
engineering graft for CNS repair. This construct design will ensure neurotrophic factor 
delivery, neural stem cell therapy and biomaterial implantation. A diagram of the model 
construct can be seen in Figure 2.33.   As can be seen, neurotrophic factor producing 
fibroblasts are encapsulated within the biopolymer alginate and NPCs are seeded on the 
surface of the construct to simulate a neural tissue scaffold.  
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Schematic representation of the multifunctional alginate construct (grey) 
containing genetically modified fibroblasts (blue) encapsulated within the 
body of the construct while continually delivering neurotrophic factors 
(pink).  Neural progenitor cells (NPCs) can be seeded on the surface of the 
construct and allowed to differentiate, acting as a neural tissue scaffold. 
Figure 2.3:. The Multi-Functional Alginate Construct 
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3. Materials 
 
3.1 Chemicals 
 
 A high guluronic acid alginate was received as a gift from FMC Biopolymer 
(Drammen, Norway) (LF200M, Batch# S15596).  N-[2-hydroxyethylpiperazine-N’–[2-
ethanesulfonic acid] sodium salt (HEPES), morpholinoethanesulfonic acid sodium salt 
(MES), poly-L-ornithine (PLO, MW 15,000-30,000), BDNF, calcium chloride, sodium 
chloride, calcium carbonate, glucono-delta-lactone (GDL), and Gelrite Gellan Gum were 
purchased from Sigma Chemical Co.(St. Louis, MO).  Natural mouse laminin (laminin 
111 derived from an EHS sarcoma) was purchased from Invitrogen (Carlsbad, CA).  
SeaPlaque Agarose (Lot# AG6418) was purchased from Cambrex BioScience Rockland, 
Inc (Rockland, Me).  
 3.1.1 Cells and Cell Culture Products 
 
 Rat abdominal skin fibroblasts genetically engineered to release brain derived 
nerve growth factor (Fb/BDNF) or neurotrophin-3 (Fb/NT-3) were kindly provided by 
Dr. Itzhak Fisher, Drexel University College of Medicine. The mouse (NB2a) 
neuroblastoma cells were kindly provided by Dr. Thomas Shea, University of 
Massachusetts, MA (Lowell Campus).  Neural progenitor cells (NPCs) derived from the 
telencephalon of embryonic day 14 mice, were provided by Dr. Justin Lathia at the 
NIH/NIA (Bayview Campus). Dulbeco’s modification of Eagles medium with and 
without glucose (DMEM), Ham’s F-12 medium, 0.25% Trypsin EDTA, L-glutamine and 
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Hank’s balanced salt solution were purchased from Fisher Scientific, (Fair Lawn, NJ). 
Antibiotics (Penicillin 100IU/ml, Streptomycin 50µg/ml), Dibutyryl cyclic adenosine 
monophosphate (dbcAMP), 0.4% Trypan blue were purchased from Sigma Chemical 
Co., St. Louis, MO. Fetal bovine serum (FBS), Serum Replacement (SR – Knockout), 
B27 was purchased from Gibco BRL, Rockville, MD.  Basic fibroblast growth factor 
(bFGF) and epidermal growth factor (EGF) were from Invitrogen. 100mm Polystyrene 
culture plates and 6 well culture plates were from Falcon, Becton Dickinson Labware, 
Franklin Lakes, NJ.  
3.2 Hydrogel Constructs 
 
3.2.1 Calcium Chloride Alginate Constructs 
 
 A 1% (w/v) alginate solution filtered with a sterile 0.45 µm syringe filter was 
loaded in a sterile 5 ml syringe with a non-beveled 21G needle. The syringe was mounted 
on a Sage syringe pump (Orion Research Inc., Beverly, MA model 355) which was 
wiped down with 70% isopropyl alcohol and placed under UV for 15 minutes in a 
laminar flow hood. The flow rate of the pump was set at 13.5ml/min. The tip of the 
needle was dipped in a tall 500 ml beaker containing 150 ml of a 1.3% (w/v) calcium 
chloride solution.  Calcium cross-linked alginate fibers were produced and were allowed 
to sit in the calcium chloride solution for an hour for hardening.  They were then washed 
sufficiently with HEPES buffer (pH 7.4). The strings had a characteristic diameter of 
300-450 µm.  
3.2.2 Calcium Sulfate Alginate Constructs 
 
 A 1% (w/v) alginate solution prepared in deionized water containing 0.2% (w/v) 
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of sodium metaphosphate.  This solution was then filtered with a sterile 0.45 µm syringe 
filter.  Alginate (5ml) was transferred to a sterile 15 ml centrifuge tube and 100 ul of a 
CaSO4 slurry (0.4 g/ml) was added to it.  The CaSO4 slurry was sterilized by autoclaving 
prior to use.  The contents of the tube were shaken vigorously to ensure complete mixing 
of the alginate and the CaSO4 slurry.  A 2 ml aliquot of the slurry was poured into each 
well of a 6 well culture plate and allowed to incubate at 37oC for 2 hours in order to 
harden.  The resulting discs were then washed sufficiently with HEPES buffer (pH 7.4) 
and had a characteristic surface are of 9.6 cm2.   
3.2.3 Calcium Carbonate-GDL Alginate Constructs 
 
 Another slow gelling process for alginate was used for experimentation.  This 
method allows for calcium carbonate, which is sparingly soluble at neutral pH to be 
slowly solubilized by the gradual dissolution of D-glucono-delta lactone (GDL) which 
lowers the pH to a level at which the carbonate has greater solubility.  A 1% (w/v) sterile 
filtered (0.45 micron bottle top filter) alginate solution was poured into a sterile 15 ml 
centrifuge tube.  An aqueous calcium carbonate suspension (5.6g/L) was added and the 
whole was mixed, followed by addition of an aqueous GDL solution (28g/L), creating a 
slurry with a final GDL concentration of 80 mM.  All aqueous solutions were first 
sterilized by autoclave.  A 2 ml aliquot of the slurry was poured into each well of a 6 well 
culture plate and allowed to incubate at 37oC for 24 hours in order to harden.  The 
resulting discs were then washed three times with HEPES buffer (pH7.4) and had a 
characteristic surface area of 9.6 cm2.   
3.2.4 Gellrite Gellan Gum Constructs 
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 A 1% (w/v) gellan gum solution was prepared in deionized water.  It was then 
sterile autoclaved and poured into a sterile 15 ml centrifuge tube. An aqueous calcium 
chloride solution was added and the solution was mixed.  All aqueous solutions were first 
sterilized by autoclave.  A 2 ml aliquot of the slurry was poured into each well of a 6 well 
culture plate and allowed to incubate at 37oC for 24 hours in order to harden.  The 
resulting discs were then washed three times with HEPES buffer (pH7.4) and had a 
characteristic surface area of 9.6 cm2.   
3.2.5 Agarose Constructs 
 
 A 1% (w/v) low melting temperature agarose solution was prepared in deionized 
water.  It was then sterilized by autoclaving.  The liquid was then poured into each well 
of a 6 well culture plate and allowed to cool to room temperature to form a solid disc.  
The resulting disc were then washed sufficiently three times with HEPES buffer (pH 7.4) 
and had a characteristic surface area of 9.6 cm2. 
3.2.6 Surface Coating of Hydrogel Constructs 
 
 Alginate, gellan gum, and agarose constructs were coated with poly-L-ornithine 
(PLO), molecular weight 15,000 - 30,000, at a concentration of 0.5mg/ml of hydrogel for 
6 minutes.  The PLO solution used was 6 times the volume of the hydrogel used for 
making the constructs.  The PLO solution was prepared in HEPES buffer just before its 
addition and was filtered using a sterile 0.2µm cellulose acetate filter.  The constructs 
were then washed sufficiently with HEPES buffer to remove any unreacted PLO. The 
constructs were then exposed to 1ml of a sterile laminin 111 (25%) solution for 24 hours.  
Finally the constructs were washed with HEPES buffer to remove excess unreacted 
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laminin 111. 
3.2.7 Peptide Conjugated (YIGSR) Alginate Constructs 
 
 YIGSR peptide was covalently attached to the alginate using an adaptation of 
aqueous carbodiimide chemistry (20). Alginate was dissolved in MES buffer (0.1 M 
MES, 0.3 M NaCl, pH 6.5) to obtain a 1% (w/v) solution. EDC was added to activate the 
carboxylic acid groups of the alginate. The amount of EDC added was such that 10% of 
the carboxylic acid groups of the alginate are activated (100 mg EDC/g alginate). This 
was followed by the addition of sulfo-NHS in the molar ratio 1:2 to EDC (28 mg sulfo-
NHS/g alginate). The solution was stirred for 15 min to allow the activation of the 
carboxylic acid groups, following which the appropriate amount of YIGSR peptide was 
added. The conjugation reaction was allowed to proceed for 24 h at room temperature 
under gentle stirring. The reaction mixture was then dialyzed for 4 days against about 20 
liters of deionized water to remove buffer salts, reaction byproducts, and unreacted 
peptide using Spectra/Por dialysis tubing (MWCO 3500). The purified YIGSR-alginate 
conjugate solution was transferred to 50 mL polypropylene tubes, and lyophilized. The 
final fibrous product was then stored in airtight tubes at -20°C for future use.  
3.3 Genetically Modified Fibroblasts 
3.3.1 Culture of Genetically Modified Fibroblasts 
 
 Rat abdominal skin fibroblasts genetically engineered to release brain derived 
nerve growth factor (Fb/BDNF) or neurotrophin-3 (Fb/NT-3) were used for 
experimentation. The retroviral vector in the fibroblasts has the human BDNF or NT-3 
transgene linked to a reporter gene LacZ, which codes for β- galactosidase [114]. 
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Fibroblasts were cultured in DMEM supplemented media with 10% FBS, antibiotics 
(Penicillin 100 IU/ml, Streptomycin 50 µg/ml), at 37°C and 5% CO2.  The cells were 
passaged using 0.25% trypsin-EDTA when they attained 70-80% confluency. 
3.3.2 Encapsulation of Genetically Modified Fibroblasts in Hydrogel Constructs 
 
 Fibroblasts (Fb/BDNF or Fb/NT-3) were harvested from culture at about 80% 
confluency using 0.25% trypsin for 3 minutes, and resuspended in sterile HEPES buffer.  
The cells, suspended in sterile HEPES, were added to the filter-sterilized (0.45 µm) 
hydrogel (alginate, gellan gum, or agarose) solution to obtain a 1% (w/v) hydrogel 
solution with a cell concentration of about 3 x 106 cells/ml of hydrogel solution. The cells 
were centrifuged, stained and counted using a haemocytometer. The protocol for 
counting cells using a haemocytometer is provided in the appendix. 
 Hydrogel constructs containing the Fb/BDNF or Fb/NT-3 were prepared and coated as 
outlined above. Fibroblast growth medium was added to the hydrogel constructs and 
incubated at 37°C.  
3.3.3 In vitro Expression of Reporter Gene 
 
 Fb/BDNF and Fb/NT-3 were stained for the β -galactosidase marker using an X-
Gal Staining Kit purchased from Genlantis (San Diego, CA).  After alginate constructs 
containing Fb/BDNF or Fb/NT-3 had been incubated at 37oC for 2 weeks, they were 
washed with PBS (pH 7.4).  Fixing Buffer was then added to each disc and incubated at 
room temperature for 15 minutes.  The fixing buffer was then removed and the disc was 
then washed sufficiently with PBS. X-Gal solution was then added to each disc and 
incubated at 37oC for 18 hours to ensure proper staining.  The X-Gal solution was then 
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removed and the discs were washed with PBS.  The discs were observed and photographs 
of the discs were taken using an Olympus IX71 fluorescence microscope.  Images were 
processed using SPOT image software to adjust intensity levels.  
3.4 NB2a (Mouse Neuroblastoma) Cells 
3.4.1 Culture of NB2a Cells 
 
 NB2a, mouse neuroblastoma cells, were cultured in 100 mm culture plates with 
DMEM (without L-Glutamine) + 10%FBS + 2mM L-Glutamine + 2mM Antibiotics. The 
cells were passaged at approximately 70-80% confluency.  
3.4.2 Seeding of NB2a Cells on Alginate Constructs 
 
 NB2a cells were harvested from culture and resuspended in serum free medium 
containing DMEM + 10% serum replacement +2 mM L-glutamine.  They were then 
seeded on the alginate constructs coated with laminin 111 as previously described. The 
final concentration of NB2a cells on the surface of the construct was 500,000 cells/ml of 
alginate. The cells were centrifuged, stained and counted using a haemocytometer. The 
protocol for counting cells using a haemocytometer is provided in the appendix. 
  After 24 hours, the constructs were washed thoroughly with Hank’s buffered salt 
solution to remove any unattached cells. 
3.4.3 Differentiation of NB2a Cells 
 
 After NB2a cells were seeded and attached for 24 hours, the alginate constructs 
were washed with Hanks salt solution to remove any unattached cells. NB2a 
differentiation medium consisting of serum free medium + 0.1% FBS + 10µM dibutyryl 
cyclic adenosine monophosphate (DbcAMP), was then added to the constructs. The 
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differentiation medium was replaced everyday to replenish the DbcAMP.   Cell 
differentiation was observed for a period of 7 days.   Photographs of the cells were taken 
using an Olympus IX71 fluorescence microscope.  Images were processed using SPOT 
image software to adjust intensity levels.  
3.5 Neural Progenitor Cells (NPCs) 
3.5.1 Culture of NPCs 
 
 NPCs derived from the telencephalon of embryonic day 14 mice and cultured in 
NPC proliferation medium consisting of DMEM/Ham’s F-12 (50:50) supplemented with 
2% B-27, 20 ng/ml bFGF (basic fibroblast growth factor) and 20 ng/ml EGF (epidermal 
growth factor) at 37oC and 5% CO2.  NPCs were cultured as colonies and passaged at 7 
days after the colonies were visibly spherical using 0.25% trypsin EDTA. 
3.5.2 Seeding of NPCs on Hydrogel Constructs 
 
 NPCs were harvested from culture after they were visibly spherical and 
resuspended in NPC differentiation medium consisting of DMEM/Ham’s F-12 (50:50) 
supplemented with 2% B-27 and 20ng/ml EFG.  They were then seeded on the alginate 
scaffold coated with laminin 111 as previously described.  The final cell concentration of 
the NPCs on the surface of the scaffold was 200,000 cells/ml of hydrogel. The cells were 
centrifuged, stained and counted using a haemocytometer. The protocol for counting cells 
using a haemocytometer is provided in the appendix.  After 24 hours, the constructs were 
washed thoroughly with Hank’s buffered salt solution to remove any unattached cells. 
3.5.3 Encapsulation of NPCs 
 
  
45 
 In order to evaluate the effectiveness the delivery of NPCs by encapsulation, cells 
were harvested from culture after they were visibly spherical and resuspended in sterile 
HEPES buffer.  The cells, suspended in sterile HEPES, were added to the filter-sterilized 
(0.45 µm) hydrogel (alginate, gellan gum, or agarose) solution to obtain a 1% (w/v) 
hydrogel solution with a cell concentration of about 3 x 106 cells/ml of hydrogel solution. 
The cells were centrifuged, stained and counted using a haemocytometer. The protocol 
for counting cells using a haemocytometer is provided in the appendix. 
 Hydrogel constructs containing the Fb/BDNF or Fb/NT-3 were prepared and coated as 
outlined above. NPC differentiation medium was added to the hydrogel constructs and 
incubated at 37°C.  
3.5.4 Differentiation of NPCs 
 
 After NPCs were seeded on or encapsulated in hydrogel constructs, they were 
allowed to differentiate.  Differentiation medium was added to the constructs and was 
replaced everyday. Cell differentiation was observed for a period of 7 days.  Photographs 
of the cells were taken using an Olympus IX71 fluorescence microscope.  Images were 
processed using SPOT image software to adjust intensity levels.  
3.6 In vitro Behavior of NB2a Cells on Alginate Constructs 
3.6.1 Quantification of Differentiation of NB2a Cells 
 
 After 7 days in culture, neurite extensions of differentiated NB2a cells were 
measured using SPOT image software.  Additionally, the number of differentiated and 
undifferentiated NB2a cells for each type of construct used, were counted in 10 adjacent 
fields. 
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3.7 In vitro Evaluation of Hydrogel Constructs Seeded with NPCs  
3.7.1 Attachment and Adhesion of NPCs 
 
 Hydrogel constructs made from equal volumes of hydrogel were made in each 
well of a 6 well culture plate. NPCs were harvested from culture, centrifuged, counted 
and resuspended in NPC differentiation medium. The constructs (with or without a 
laminin 111 coat) were seeded with 200,000 cells per well and incubated at 37°C at 5% 
CO2 for 24 hours. After 24 hours, the constructs were washed thoroughly with Hank’s 
buffered salt solution to remove any unattached cells. The constructs were then treated 
with 0.25% trypsin for 5 minutes to detach the cells from the constructs and resuspended 
in NPCs differentiation medium. The cells were centrifuged, stained and counted using a 
haemocytometer. The protocol for counting cells using a haemocytometer is provided in 
the appendix. 
3.7.2 Viability of NPCs 
 
 For cell viability the Live/Dead Reduced Biohazard Viability/Cytotoxicity Kit 
#1(Invitrogen) was used.  NPCs seeded on hydrogel constructs were incubated for 15 
minutes at room temperature with Component A (live stain) and Component B (dead 
stain).  Cells were then fixed in 4% glutaraldehyde (Sigma, St. Louis, MO) for 1 hour at 
room temperature.  Images were acquired using an Olympus IX71 fluorescence 
microscope.  Images were processed using SPOT image software to adjust intensity 
levels. Images of stained cells in 10 adjacent fields were then counted blindly for each 
marker. Each field represented 0.3 mm2. The following counts were made in each field: 
the total number of cells (phase contrast), and the number of cells expressing the marker 
  
47 
of interest, Component A or B. These data were used to calculate the percentage of cells 
(phase contrast) labeled with Component A or B.   
3.7.3 Migration Distance of NPCs 
 
 After NPCs had attached and differentiated for 5 days, the migration distance of 
cells was quantified to evaluate the differentiation potential of NPCs.  This was done by 
measuring the radius of the original NPC colony and measuring the radius of migration 
distance of the cells out of the original colony (Fig 3.14).  These two values were 
compared as a ratio (Migrated Radius: Original Radius) to normalize all NPC colony 
sizes.  10 adjacent fields were quantified for migration distance for each type of 
construct. Each field representing 0.24 mm2 (546 µm × 438 µm) 
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Figure 4. Calculation of Migration Distance of NPCs 
Migration distance calculation example and presence of neurotrophic receptors in the 
NPCs.  Photomicrograph of a seeded colony of NPCs.  Migration distance of NPCs was 
calculated as a ratio of outer migration distance to the radius of the original NPC colony, 
scale bar = 100µm. 
 
 
Figure 3.1: Calculation of Migration Distance 
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3.7.4 Immunohistochemical Staining of NPCs 
 
In order to adequately study the differentiation of NPCs, immunohistochemical staining 
was performed.  For this procedure cells were fixed in 2% PFA (paraformaldehyde, 
Sigma, St. Louis, MO) for 30 minutes at room temperature.  Fixed cells were blocked for 
a minimum of 30 min in PBS containing 0.1% Triton X-100 (Amresco) and 10% normal 
goat serum (Sigma) to block non-specific antibody binding, followed by incubation 
overnight with the relevant primary antibodies at 4°C.  After the samples were incubated 
with the appropriate secondary antibodies and subsequently washed three times with PBS 
to remove the unreacted antibodies, DAPI counter-staining was used when required, and 
images were acquired using an Olympus IX71 fluorescence microscope.  Images were 
processed using SPOT image software to adjust intensity levels.  The following 
antibodies (Stem Cell Technologies Inc) and concentrations were used for neurotrophic 
factor receptor immunohistochemistry: anti-p75 (mouse IgG2a, 1:100), anti-Trk B (mouse 
IgG2a, 1:100), anti-Trk C (mouse IgG2a, 1:100).   
For lineage specific staining of NPCs, the following antibodies and concentrations were 
used: anti-neuronal class III β tubulin (mouse IgG2a, 1:1000), anti- MAP-2 kinase (mouse 
IgG2a, 1:500), anti-GFAP (rabbit polyclonal, 1:200),  anti-S100b (rabbit polyclonal, 
1:200), anti-GalC (rabbit polyclonal, 1:200), and anti CNPase (rabbit polyclonal, 1:200).  
The appropriate lineage markers for each stain can be seen in Table 2-1. Appropriate 
Alexa Fluor 488 and Alexa Fluor 568 – conjugated IgG (1:100 – 1:500, Invitrogen) were 
used as secondary antibodies.  Images of stained cells in 10 adjacent fields were then 
counted blindly for markers for each phenotype. Each field represented 0.3 mm2. The 
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following counts were made in each field: the total number of cells (phase contrast), and 
the number of cells expressing the primary antibody of interest (anti ß-III tubulin, anti 
MAP-2 kinase, anti GFAP, anti S100b, anti GalC, and anti CNPase),. These data were 
used to calculate the percentage of cells (phase contrast) labeled with the primary 
antibody.   
 
 
 
 
Table 3.1: Characterization of Antibodies For Immunohistochemistry 
Antibody 
 
Marker 
ß-III Tubulin 
 
Neuron 
MAP-2-kinase 
 
Neuron 
CNPase 
 
Oligodendrocyte 
GalC 
 
Oligodendrocyte 
GFAP 
 
Astrocyte 
S100b 
 
Astrocyte 
 
 
 
 
 
  
51 
3.8 In vivo Evaluation of Alginate Constructs 
 
3.8.1 Surgical Procedures (Brain and Spinal Cord) 
 
 C57BL/6 male mice (for brain injury model) were purchased from The Jackson 
Laboratory (Bar Harbor, ME) and maintained in the animal facility at the National 
Institute on Aging (NIA) under pathogen-free conditions on a 12-h light/12-h dark cycle 
with continuous access to food and water.  All procedures were approved by the National 
Institute on Aging Animal Care and Use Committee. Mice were anesthetized using the 
inhalation anesthetic Isoflurane (2 ½- 5%) mixed with oxygen.  Animals were maintained 
under anesthesia throughout the procedure.  The level of anesthetic was assessed by 
monitoring respiration (>20/min), corneal reflex (air puff to eye) and leg jerk in response 
to pressure on the tail or hind paw.  The areas of incision (scalp) was shaved with a #40 
clipper blade and swabbed with 70% alcohol and betadine solution.  All surgical 
instruments were autoclaved prior to use in a hot bead sterilizer.  A sagittal incision was 
made in the scalp, and the skull was exposed. For a non-injury model, a 3-5 mm hole was 
drilled in the scalp with a dremmel drill, after which, the alginate construct was placed on 
the brain parenchyma For a brain injury model, a 3-5 mm hold was made in the scalp and 
then a sterile needle was inserted at predetermined locations in the brain parenchyma 
using stereotaxic coordinates. The injection cannula was left in place for 3 minutes, after 
which, the alginate construct was placed on the site of injury (with the DiI labled NPCs 
on bottom surface).  Following surgery, the skull hole was packed with gel foam and the 
skin overlying the skull was sutured shut. The animals were placed on a surgical water 
heating pad during recovery from anesthesia and monitored every hour for 10 hours for 
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recovery. The animals were then housed in the animal care quarters until required for the 
experimental analysis. 
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Figure 3.2 Brain Injury Model and Alginate Construct Transplantation 
 
Schematic representing the stab wound injury (red) in the cerebral cortex of the mouse 
brain.  The alginate construct (blue) was transplanted at the site of injury with the DiI 
labeled NPCs on the bottom surface, touching the injury. 
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 Long Evans rats (for spinal cord transection) were purchased from The Jackson 
Laboratory (Bar Harbor, ME) and maintained in the Calhoun Animal Facility under 
pathogen-free conditions on a 12-h light/12-h dark cycle with continuous access to food 
and water. All procedures were approved by the Drexel University Animal Care and Use 
Committee. Rats were anesthetized using the inhalation anesthetic Isoflurane (2 ½- 5%) 
mixed with oxygen.  Animals were maintained under anesthesia throughout the 
procedure.  The level of anesthetic was assessed by monitoring respiration (>20/min), 
corneal reflex (air puff to eye) and leg jerk in response to pressure on the tail or hind paw.  
The areas of incision (back) was shaved with a #40 clipper blade and swabbed with 70% 
alcohol and betadine solution.  All surgical instruments were autoclaved prior to use in a 
hot bead sterilizer. An incision was made in the back and the spinal musculature was 
reflected from the dorsal spine. A laminectomy was performed with a micro-rongeurs at 
the T9-10 spinal level for transection. The dura was incised at the midline to expose the 
spinal cord. The entire spinal cord was transected at the T9-10 section with a scalpel and 
aspirated to create a lesion cavity. The lesion cavity was then filled with the alginate 
construct (with the DiI labled NPCs on the top surface), and the dura, muscle, and skin 
sutured closed. After surgery, rats were observed until fully awake, being kept on heating 
pads, before being returned to the home cages. Post-surgical pain management was 
achieved with Buprenex (0.05 mg IM) before completion of surgery and then every 12 
hours for 48 hours post-op. The animals were then housed in the animal care quarters 
until required for the experimental analysis. 
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Figure 3.3 Spinal Cord Transection and Alginate Construct Transplantation 
 
Schematic representing the transection of the rat spinal cord at the T9-T10 section.  
The alginate construct  (red and blue) was placed at the site of the transection with 
the DiI labled NPCs on the top surface (red) 
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3.8.2 Histological Analysis of Transplant Tissue without NPCs 
 
 In order to adequately evaluate the in vivo effectiveness of alginate constructs, a 
histological analysis of transplant tissue was performed. Brains of the previously 
transplanted animals were retrieved after a paraformaldehyde (PFA) perfusion and then 
fixed in 4% PFA in PBS overnight at 4°C before being transferred to sequential 20% and 
30% solutions of sucrose (w/v) and left at 4°C overnight or until the brains equilibrated.  
The brains were then embedded in TissueTek (Sakura) prior to cryostat sectioning (7 µm, 
Leica CM3050S).  Sections were counter-stained with 4',6-Diamidino-2-phenylindole 
dihydrochloride (Dapi, Sigma) in order to visualize the DNA and images were acquired 
using an Olympus IX50 fluorescence microscope.  Images were processed and adjusted 
using MagnaFire and Photoshop 6.0 (Adobe) to include the entire signal within the 
dynamic range.  For cell death analysis, a TUNEL (terminal deoxynucleotidyl transferase 
biotin-dUTP nick end labeling) assay kit (Millipore) was used.  For BDNF staining, the 
sections were first quenched with 0.3% hydrogen peroxide for 30 min and then treated 
for 20 min with a blocking buffer containing PBS with 5% normal goat serum (Sigma) 
and 0.3% triton X-100 (Sigma).  Sections were then incubated overnight at 4°C with an 
anti-mouse IgG2a BDNF primary antibody (Santa Cruz, sc8042) at a 1:200 dilution in 
blocking solution.  The sections were then washed sufficiently with PBS and exposed to a 
biotinylated anti-mouse secondary antibody (Vector Labs BA-2000) at a 1:100 dilution in 
blocking solution for 90 min at 25°C.  After sufficient washing with PBS, the sections 
were incubated at 25°C for 60 min with the ABC solution from a VECTASTAIN® ABC 
kit (Vector Labs PK-4000).  After sufficient washing with PBS, all the sections were 
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placed into the same glass exposure chamber and exposed to a 3,3’-diaminobenzidine 
(DAB, Vector SK-4100) reaction.  The reaction was stopped after significant color was 
produced (10 min) and the sections were sufficiently washed with PBS.  The sections 
were then dried thoroughly and dehydrated in a graded ethanol wash (70% for 5 min, 
90% for 5 min, 100% for 5 min) and finally washed with 100% xylene for 10 min.  The 
slides were then mounted with a  coverslip using Cytoseal XYL (Stephens Scientific) and 
visualized with a Nikon Eclipse E600 microscope with identical light exposure 
conditions.  Images were processed with IPLab software (BD Biosciences) and 
Photoshop 6.0 (Adobe).  
3.8.3 In vivo expression of Reporter Gene 
 
 Fb/BDNF were stained for the β -galactosidase marker using an X-Gal Staining 
Kit purchased from Genlantis (San Diego, CA).  After alginate discs containing 
Fb/BDNF had been implanted in mice for 7 days, they were recovered and washed with 
PBS (pH 7.4).  Fixing Buffer was then added to each disc and incubated at room 
temperature for 15 minutes.  The Fixing Buffer was then removed and the disc was then 
washed sufficiently with PBS. X-Gal solution was then added to each disc and incubated 
at 37oC for 18 hours to ensure proper staining.  The X-Gal solution was then removed 
and the discs were washed with PBS.  The discs were observed and photographs of the 
discs were taken using an Olympus IX71 fluorescence microscope.  Images were 
processed using SPOT image software to adjust intensity levels.  
3.8.4 Fluorescent (DiI)  Labeling of NPCs 
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 After NPCs were cultured as colonies and passaged at 7 days after the colonies 
were visibly spherical, a vybrant DiI live cell tracker solution was added to the cell 
culture at a concentration of 5 µl per 1X106 cells.  The cell culture was incubated at 37oC 
for 30 minutes in order for the dye to perfuse the cells and then washed 3x with NPC 
differentiation medium.  The labeled cells were seeded on the constructs as previously 
described at a concentration of 200,000 cells per ml of alginate. 
3.8.5 Histological Analysis of Brain and Spinal Cord Tissue After Surgical       
         Implantation of Alginate Construct with DiI Labeled NPCs 
 
  In order to adequately evaluate the in vivo effectiveness of alginate constructs, a 
histological analysis of transplant tissue was performed. Brains of the previously 
transplanted animals were retrieved after a paraformaldehyde (PFA) perfusion and then 
fixed in 4% PFA in PBS overnight at 4°C before being transferred to sequential 20% and 
30% solutions of sucrose (w/v) and left at 4°C overnight or until the brains and spinal 
cords equilibrated.  The tissue was then embedded in M1 medium (Sakura) prior to 
cryostat sectioning (7 µm, Leica CM3050S). The tissue sections were then blocked with 
2% BSA + 0.1% Triton X-100 with 300 ul added per slide .  The primary antibody 
(NeuN or GFAP) was added to the blocking buffer (1:100 concentration in blocking 
buffer) and 100 ul/slide was added to the tissue sections and kept at 4 oC overnight.   The 
slides were then washed with 1X PBS, three times, each time waiting for 2-3 mins.  The 
secondary antibody (Alexafluor 488, 1:100) was then added at 100 ul/slide and incubated 
at room temperature for 45 minutes.  The slides were then washed three times with PBS. 
Sections were counter-stained with 4',6-Diamidino-2-phenylindole 
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dihydrochloride (Dapi,  Sigma) in order to visualize the DNA and images were acquired 
using an Olympus IX50 fluorescence microscope.  Images were processed and adjusted 
using MagnaFire and Photoshop 6.0 (Adobe) to include the entire signal within the 
dynamic range.  
3.8.6 Histological Analysis of Spinal Cord Tissue After Surgical  Implantation of 
Alginate Construct with DiI Labeled NPC 
 
  3 mm sections rat spinal cords (including transected section) of the 
previously transplanted animals were retrieved after a paraformaldehyde (PFA) perfusion 
and then fixed in 4% PFA in PBS overnight at 4°C before being transferred to sequential 
20% and 30% solutions of sucrose (w/v) and left at 4°C overnight or until the spinal 
cords equilibrated.  The tissue was then embedded in M1 medium (Sakura) prior to 
cryostat sectioning (7 µm, Leica CM3050S).  The tissue sections were then blocked with 
2% BSA + 0.1% Triton X-100 with 300 ul added per slide .  The primary antibody 
(NeuN or GFAP) was added to the blocking buffer (1:100 concentration in blocking 
buffer) and 100 ul/slide was added to the tissue sections and kept at 4 oC overnight.   The 
slides were then washed with 1X PBS, three times, each time waiting for 2-3 mins.  The 
secondary antibody (Alexafluor 488, 1:100) was then added at 100 µl/slide and incubated 
at room temperature for 45 minutes.  The slides were then washed three times with PBS. 
Sections were counter-stained with Dapi, in order to visualize the DNA and images were 
acquired using an Olympus IX50 fluorescence microscope.  Images were processed and 
adjusted using SPOT Image software to include the entire signal within the dynamic 
range.  Quantification of phenotypical staining in the spinal cord tissue was done through 
a stereological analysis of the transplant tissue.  15 tissue sections (horizontally cut) that 
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contained DiI positive NPCs were quantified blindly for each marker. Each field 
represented 0.4 mm2. The following counts were made in each field: the total number of 
cells (Dapi), the total number of migrated NPCs (DiI), and the number of cells expressing 
the marker of interest (anti-GFAP and anti-NeuN). These data were used to calculate the 
percentage of cells (Dapi) labeled with DiI and anti-GFAP or anti-NeuN.   
 
3.9 Statistical Analysis 
  
 
 Statistical analysis for all data for comparison was performed by one-way analysis 
of variance (ANOVA) followed by a Tukey-Kramer test using Graphpad PRISM 
software.  p>0.05 was used for significance.  All cell counts were analyzed in a blinded 
manner.
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4. Results and Discussion 
 
 The main goal of this thesis was to create a novel, implantable alginate construct 
for CNS injury repair.  Preliminary data were collected by monitoring the effect of 
alginate constructs using the mouse neuroblastoma (NB2a) cell line as a model.  NB2a 
attachment and differentiation patterns were observed on the surface of alginate 
constructs.  These results were then used in order to demonstrate the ability of these 
constructs to support NPC attachment, preserve viability, and initiate lineage 
differentiation of cultured NPCs. Three different hydrogel constructs were evaluated and 
their use as scaffolding materials to support NPC attachment and viability was studied. 
Finally, the effectiveness of the alginate construct for CNS injury repair was studied 
through in vivo models. 
4.1 NB2a Cell Studies 
4.1.1 NB2a Differentiation by Alginate Constructs 
 
 NB2a cells have previously been shown to attach and differentiate on laminin 111 
(a heterotrimeric extracellular matrix (ECM) protein) coated calcium chloride and 
calcium sulfate crosslinked alginate constructs [52].   Hence, because of their availability 
and ease in culturing, NB2a cells were used as a preliminary cell model for neural cell 
attachment and differentiation on the multi-functional alginate constructs crosslinked 
with calcium from calcium carbonate.  The rationale for performing this study was to 
study the effect of peptide modification on these novel alginate constructs with 
encapsulated neurotrophic producing fibroblasts as well as to evaluate the potential of a 
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growth permissive surface for neural stem cells along their surface.  Differentiation of the 
NB2a cells can be seen in Figure 4.1. Laminin 111 coated alginate discs with 
encapsulated Fb/BDNF or Fb/NT-3 were seeded with undifferentiated NB2a cells.  Under 
normal culture conditions, NB2a cells require the differentiation factor dibutyryl cyclic 
adenosine monophosphate  (dbcAMP) in order to differentiate[52].  As an experimental 
test of the construct, dbcAMP was not added to the media. After 7 days, NB2a cells 
surprisingly attached, differentiated, and extended on the surface of fibroblast 
encapsulated alginate constructs without the presence of dbcAMP (average length on 
Fb/BDNF construct: 188.8 ± 14.5µm; Fb/NT-3 construct: 121.08 ± 10.9µm; p<0.01).  
However, when Fb/BDNF or Fb/NT-3 were not encapsulated in the alginate construct 
and dbcAMP was not added, differentiation was not observed (Fig. 4.2).  Neural 
differentiation of NB2a cells seeded on alginate constructs with encapsulated Fb/BDNF 
was comparable to NB2a cells grown on fibroblast free alginate discs with supplemented 
dbcAMP (average length on Fb/BDNF construct: 188.8 ± 14.5µm, fibroblast free + 
dbcAMP construct: 183.2 ± 16.9 µm; p>0.05). However, when fibroblasts were 
encapsulated within the construct and dbcAMP was added to the medium, extensive 
NB2a differentiation and extension was observed (Average length on Fb/BDNF + 
dbcAMP construct: 214.5 ± 11.7µm; Fb/NT-3 + dbcAMP construct: 194.4 ± 10.9µm, 
p<0.01). This leads to the conclusion that alginate encapsulated Fb/BDNF or Fb/NT-3 
promote the extensive differentiation of NB2a neuroblastoma cells without the 
incorporation of differentiation factors. Additionally, alginate encapsulated Fb/BDNF or 
Fb/NT3 enhances the differentiation of NB2a cells with the incorporation of 
differentiation factors.  This is mainly due to the fact that neurotrophic factors seem to 
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enhance neuronal survival, growth and differentiation when administered[16, 18, 44, 47, 
49, 65]. Additional studies were done where NB2a cells were initially supplemented with 
BDNF and never replenished, but minimal differentiation was observed.   This suggests 
that the continuous release of BDNF from the encapsulated fibroblasts within the alginate 
construct is the stimulus for differentiation of the NB2a cells.   
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 Since alginate constructs with encapsulated neurotrophic factor producing 
fibroblasts were shown to increase the average length of neurites extending from 
differentiated NB2a cells seeded on the surface, the percentage of differentiated NB2a 
cells as compared to undifferentiated cells was then quantified (Fig. 4.3). NB2a cells 
seeded on alginate constructs with encapsulated neurotrophic factor producing fibroblasts 
(both Fb/BDNF and Fb/NT-3) showed a high amount of differentiated cells after 7 days 
in culture (differentiated NB2a cells on Fb/BDNF construct: 55.8 ± 3.6%; Fb/NT-3 
construct: 54.3 ± 4.3%) significantly more than the alginate construct supplemented with 
dbcAMP and without any encapsulated fibroblasts (differentiated cells: 45.1 ± 4.3%; 
p<0.001).  Alginate constructs not supplemented with dbcAMP and without encapsulated 
fibroblasts did not promote any differentiation.  However, when fibroblasts were 
encapsulated within the alginate construct (Fb/BDNF or Fb/NT3) and dbcAMP was 
supplemented in the growth media, a significantly high number of NB2a cells showed 
extensive differentiation (differentiated cells on Fb/BDNF +dbcAMP construct: 74.5 ± 
2.2%; Fb/NT3 + dbcAMP construct: 70.6 ± 1.75%).  This indicates that the alginate 
constructs with encapsulated fibroblasts increased the amount of differentiated cells 
because of their continuous release of growth factors and interaction with the construct.  
The significance of these findings is that this further solidifies the fact that the continuous 
release of growth factors along with the alginate itself have been shown to induce 
differentiation of NB2a cells and hence may possess these same unique properties and 
influence the cells in the injury environment when the construct is implanted in vivo.  
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Figure 7. Percentage of Differentiated NB2a Cells on Alginate Constructs                                          
Graph representing the percent of differentiated NB2a cells on disc-shaped 
alginate constructs.  All quantification was done after NB2a cells had attached 
and differentiated for 7 days in culture (n=10). * and **  (p<0.001 and p<0.01) 
Figure 4.3: Percentage of Differentiated NB2a Cells on Alginate Constructs 
Composition of Construct 
* * 
* 
** 
** 
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4.2 Viability of Encapsulated Fibroblasts in Hydrogel Constructs and an           
      Optimal Cell Growth Environment 
 
 As previously stated, an important design component of fabricating a hydrogel 
construct for CNS repair is a demonstrated lack of toxicity while at the same time having 
the ability to continually release neurotrophic factors over an extended period of time at 
the site of injury.  In order to assess the ability of the encapsulated fibroblasts to produce 
BDNF and NT-3 within the fabricated alginate constructs, a staining assay for the β-
Galactosidase marker was conducted.  Positive staining of the fibroblasts for the reporter 
gene was observed 14 days after encapsulation in the calcium carbonate (CaCO3) 
crosslinked alginate discs (Fig 4.4).  The reporter gene staining observed in the cells 
encapsulated in alginate constructs was similar to that observed in Fb/BDNF that had not 
been encapsulated which shows that transgene expression continued after the 
encapsulation procedure .  Since β-Galactosidase is a marker it can be concluded that the 
fibroblasts also continue to express neurotrophic factors (BDNF and NT-3) two weeks 
after encapsulation in alginate. Additionally, fibroblasts encapsulated within calcium 
chloride (CaCl2) and (CaSO4) crosslinked alginate constructs showed a positive transgene 
expression through reporter gene staining.   
 Moreover, two hydrogels of a similar polysaccharide nature (gellan gum and 
agarose) were tested in order to determine if alginate had distinct properties. Fibroblasts 
encapsulated within gellan gum and agarose did not report for the ß-Galactosidase marker 
after 14 days.  Hence, it can be assumed that gellan gum and agarose do not allow for 
transgene expression and therefore additional studies were conducted in order to further 
elucidate their effectiveness as a biomaterial for construct development.  
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Figure 8. Staining for β-Galactosidase Marker in Alginate Encapsulated 
Fibroblasts  
Micrographs showing positive β-Galactosidase staining of calcium crosslinked 
alginate discs  (CaCO3) with encapsulated A).BDNF producing fibroblasts and B). 
NT3 producing fibroblasts at day 14, scale bar =100µm 
 
Figure 4.4:  Staining for ß-Galactosidase Marker in Alginate Encapsulated Fibroblasts 
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 Since it is known that an optimal cell growth environment has a pH between 7.2 
and 7.4 [88] a study was done in order to determine if the environment provided by the 
alginate scaffolds was pH compatible for NPCs. The pH of the culture medium above 
seeded scaffolds incubated in vitro was measured after 4 days using calcium-alginate gels 
with encapsulated Fb/BDNF/NT3, crosslinked in the three different ways; calcium 
chloride (CaCl2), calcium sulfate (CaSO4) and calcium carbonate (CaCO3).  Alginate 
constructs crosslinked with Ca2+ from calcium carbonate showed the optimal pH for cell 
growth (7.3 ± 0.2, p<0.001) after 4 days in culture (Table 1).  However, alginate 
constructs crosslinked with Ca2+ from calcium sulfate and calcium chloride showed a 
more acidic cell growth environment (pH of media in CaSO4 construct: 5.1 ± 0.2, CaCl2 
construct: 5.0 ± 0.1, p>0.05). This may be due to the existence of the different anions 
remaining in the gels after cross linking, and replacement of the Ca2+ of the salt with the 
H+ of the alginic acid. Sulfate and chloride ions remaining from the CaSO4 and CaCl2 
will not associate with protons from the water, resulting in acids that are classified as 
extremely strong acids, whereas CO32- ions will associate to form carbonic acid, 
classified as a weak acid and an excellent buffering agent.  Hence, the measured 
difference in pH can be attributed to the fact that the alginate constructs crosslinked with 
Ca2+ from calcium carbonate contained bicarbonate ions that acted as buffering agents 
against toxic cell by-products within the culture media.  Since the characteristic 
crosslinking of calcium-carbonate-GDL-alginate discs is by the slow solubilization of 
calcium carbonate by the gradual dissolution of D-glucono-delta lactone (GDL), 
bicarbonate ions are slowly and steadily released into the culture medium[73]. Once the 
GDL has completely dissolved, it can be concluded that the release and presence of 
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bicarbonate ions allows for the calcium carbonate-GDL-alginate discs to provide a 
favorable cell growth environment.  Additionally, fibroblasts encapsulated within gellan 
gum and agarose (two polysaccharide hydrogels) showed an acidic environment as well 
(pH of media in gellan gum construct: 4.9 ± 0.2, agarose construct: 5.1 ± 0.1, p>0.05).  
These constructs were not significantly different from CaSO4 or CaCl2 alginate 
crosslinked constructs (p>0.05), but were significantly acidic as compared to CaCO3 
alginate crosslinked constructs (p<0.001). 
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Table 4.1: pH of Media on Hydrogel Constructs With Encapsulated Fibroblasts 
After 4 days (n-6) 
 
Construct 
 
pH of Media After 4 Days 
 
Alginate + CaSO4 
 
 
5.1 ± 0.2 
 
 
Alginate + CaCl2 
 
 
5.0 ± 0.1 
 
 
Alginate + GDL+ CaCO3 
 
 
7.3 ± 0.2  * 
 
 
Gellan Gum 
 
4.9 ± 0.2 
 
Agarose 
 
5.1 ± 0.1 
* (p<0.001) 
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4.3 NPC Studies 
 
 Since the main goal of this thesis was to use the alginate constructs that deliver 
neurotrophic factors (BDNF and NT-3) as scaffolds for NPC growth and differentiation, 
the behavior of NPCs on the surface of these constructs was studied in detail.  Using the 
aforementioned results of the model NB2a cell line, it was concluded that alginate acts as 
an optimal surface for cell differentiation with a favorable cell growth environment and 
hence, the effect of alginate on NPCs was then observed and evaluated. Proliferation and 
survival NPCs after encapsulation in alginate has been previously reported [86] but not 
alginate’s effect when cells are grown on the surface,  which motivated our detailed 
study. 
4.3.1. Verification of Stem Cell Properties of NPCs 
 
 NPCs are a unique type of cell line since they can give rise to all three neuronal 
cell types (neurons, oligodendrocytes, and astrocytes).  Equally as important is the ability 
of NPCs to self-renew and continually proliferate into large cell colonies[53, 55, 60, 89, 
90].  Hence, in order to ensure that the cells that were to be used in this study were in fact 
true NPCS with these properties, cells were cultured as large colonies (Fig 4.5 A) and 
then dissociated into a single cell culture through the addition of trypsin (Fig 4.5 B).  4 
days after dissociation, the cells began to re-form into colonies (Fig 4.5 C), giving 
evidence that the cells did indeed have the ability to self-renew. Additionally when plated 
on poly-L-lysine (PLL) coated culture dishes, the NPCs differentiated into neurons (Fig 
4.6 A), oligodendrocytes (Fig 4.6 B) and astrocytes (Fig 4.6 C); all three neuronal 
lineages.  Hence, the cells were verified to have stem cell properties and were true NPCs.  
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Figure 10. Differentiation of NPCs 
NPC spherical colonies were grown and differentiated into all three distinct 
lineages on poly-L-Lysine (PLL) coated coverslips and were positive for ß-
tubulin  (neurons) (A), CNPase (oligodendrocytes) (B) and GFAP (astrocytes) 
(C). Scale bar = 100 µm 
 
Figure 4.6: Differentiation of NPCs 
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4.3.2 Surface Attachment of NPCs to Hydrogel Constructs 
 
 To date, studies reported in the literature have primarily concentrated on showing 
the potential of NPCs for regeneration, proliferation, and lineage differentiation after 
direct implantation of undifferentiated cells into an injury site [53, 91].  Additionally, 
NPCs and other cells have also been encapsulated within different hydrogels and matrices 
and implanted into injured CNS regions [51, 61, 63, 92-94]. The potential drawbacks of 
these immobilization strategies are that cell encapsulation significantly increases the time 
required for these cells to begin their regenerative/differentiation process because the 
encapsulating agent has to be sufficiently degraded before the cells can be released from 
the matrix and integrate into the host tissue.  This in turn leads to extremely limited cell 
proliferation and potentially reduces the regenerative capacity of this delivery strategy for 
NPCs and other cell lines [92-94]. Prang et al. have reported encapsulation of NPCs in 
alginate in the form of so called “anisotropic capillary hydrogels” which have the 
advantage of having a hexagonally structured anisotropic capillary gel structure which 
promotes directed axonal regrowth [62] .  Others, including Ashton et al., have attempted 
to encapsulate degrading enzymes within the matrix in order to allow for sufficient NPC 
release [86].  However, the in vivo consequences of the delivery of this foreign enzyme 
remain unclear. 
 In order to test the effectiveness of using alginate surfaces as a scaffolding 
material for NPC growth as well as a 3D matrix for neurotrophic factor delivery from 
genetically altered cells, the surface attachment of NPCs to it and two other hydrogels 
derived from polysaccharides (gellan gum and agarose) and a laminin 111 coating were 
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studied. Hence, ~200,000 cells were seeded on both plain and laminin 111-coated 
alginate, gellan gum, and agarose constructs in the form of flat discs.  Fb/BDNF and 
Fb/NT3 were encapsulated in some of the constructs as well.  After just 1 day in culture, 
NPCs showed attachment to the alginate constructs with a laminin 111 coat (~58% of 
total cells seeded) while fewer cells attached to alginate constructs without a laminin 111 
coating (~30% ) (Fig. 4.7).   The addition of neurotrophic factor producing fibroblasts 
seemed to enhance NPC attachment as well (Plain alginate construct +Fb/BDNF: ~41%; 
plain alginate construct +Fb/NT3: ~33%; laminin 111 coated alginate construct 
+Fb/BDNF: ~84% ; laminin 111 coated alginate construct + FB/NT3: ~82%).  NPCs 
attached to the flat laminin coated alginate constructs showed differentiation and cell 
migration out of the original colonies. Interestingly, gellan gum constructs seemed to 
hinder NPC attachment (plain gellan gum construct: ~19%;  laminin 111 coated gellan 
gum construct: ~27%). All variations of the agarose constructs failed to promote any 
attachment and hence quantification could not be performed. This could possibly be due 
to the fact that laminin 111 does not sufficiently coat the agarose or gellan gum because 
of their lack of a surface charge.  While it was observed that the alginate seemed to 
promote some attachment (~30%) even without a laminin coat, gellan gum (~19%) and 
agarose (0%) provided minimal attachment.  Alginate seems to act as a better substrate 
for laminin 111 and amplifies the binding potential of the neurotrophic factor release 
from the encapsulated fibroblasts.  Therefore, an alginate construct appeared to be 
permissive for cell survival and attachment and was used in further experimentation as 
the biomaterial of choice.   
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4.3.3 Viability of NPCs on Hydrogel Constructs 
 
 In order to further test the effectiveness of alginate as a suitable surface 
scaffolding material for NPC growth and a matrix  for neurotrophic factor delivery, a 
viability assay was performed.  Constructs were formed into the shape of discs and 
coated with laminin 111 .  Compared were, alginate, gellan gum, and agarose (Fig 4.8).  
Alginate constructs with and without encapsulated neurotrophic factor producing 
fibroblasts (both Fb/BDNF and Fb/NT-3) showed the highest NPC survival after 7 days 
in culture (cells alive on fibroblast free construct: 79.8 ± 9.3%; Fb/NT-3 construct: 89.0 ± 
3.1%; Fb/BDNF construct: 89.6 ± 4.6%;), significantly more than control laminin 111 
coated culture dishes (cells alive: 69.0 ± 10.5%; p< 0.001).  Gellan gum constructs failed 
to provide a favorable cell growth environment and a considerably high amount of cells 
did not survive after 7 days in culture on the scaffold (cells alive on Fb/NT-3 construct: 
28.2 ± 5.6%; Fb/BDNF construct: 21.9 ± 8.5%; p> 0.05).  Agarose constructs did not 
promote any cell attachment and hence cell viability tests could not be performed or 
quantified.  
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Figure 12.  Neural Progenitor Cell Viability on Hydrogel Constructs                                        
Graph representing the cell viability of NPCs on hydrogel constructs coated with 
laminin 111 and encapsulated neurotrophic factor producing fibroblasts evaluated by 
calculating the percentage of live and dead .differentiated NPCs seeded on alginate, 
agarose, or gellan gum (n=10). No attachment for agarose constructs. * (p<0.001) 
 
Figure 4.8: NPC Viability on Hydrogel Constructs 
Composition of Construct 
* 
* 
* 
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4.3.4 Differentiation of NPCs on Alginate Constructs 
 
 Given the effectiveness of alginate to promote NPC growth and survival, further 
studies were done on alginate construct and a laminin 111 coating were assessed as well.  
Previous work has shown that alginate constructs coated with fragments of  YIGSR (a 
laminin binding motif) and in the shape of strings (350-450 µm diameter) can allow for 
NB2a cells to attach and act as a guidance scaffold for neurite differentiation [52].  NPCs 
possess unique properties as in that they can self renew as previously shown and migrate 
and  differentiate when attached to a favorable surface (Fig 4.9).  Hence, in order to test 
the effectiveness of alginate as a scaffolding material for NPC attachment, cells were 
seeded on laminin 111-coated alginate constructs in the shape of strings and flat discs 
(Fig 4.9).  After just 1 day in culture, cells showed extensive attachment (Fig 4.9 B), 
while very few cells attached to alginate scaffolds without a laminin 111 coating. NPCs 
that showed attachment to the laminin coated alginate strings did not differentiate, 
migrate or proliferate as expected and after 5 days in culture (Fig 4.9 A), NPCs that had 
attached to alginate strings subsequently detached and died. This could be due to the fact 
that alginate strings did not provide enough surface area ( 300-450 µm in diameter) for 
NPCs to sufficiently attach.  However, when cells were seeded on flat laminin coated 
alginate discs , they showed attachment, differentiation and cell migration out of the 
neurospheres after 3 and 5 days (Fig 4.9 C and D).  Similar attachment was observed 
when neurotrophin producing fibroblasts (BDNF and NT-3) were encapsulated within the 
alginate constructs.  Hence, a flat surfaced disc appeared to be permissive for cell 
survival and attachment and was used in further experimentation as the alginate construct 
of choice. 
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Figure 13. Attachment and Differentation of NPCs on Alginate Constructs 
Micrographs of NPC attachment to laminin 111 coated alginate constructs in 
the shape of strings after 1 day (A) and discs after 1 (B) , 3 (C) , and 5 (D) days 
in culture, scale bar = 100 µm. 
A. B. 
C. D. 
Figure 4.9: Attachment and Differentiation of NPCs on Alginate Constructs 
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4.3.5 Migration of NPCs 
 
 These aforementioned studies demonstrated that laminin 111-coated alginate in 
the shape of a disc yields high cell viability and attachment, and therefore quantification 
of the migration of NPCs on these alginate constructs was also evaluated. Our previous 
work using NB2a mouse neuroblastoma cells, demonstrated that native alginate elicited 
minimal cell attachment (~1.5%); however YIGSR-alginate conjugate discs (discs coated 
with alginate conjugated to fragments of the laminin peptide (YIGSR)) elicited a fivefold 
increase in numbers of cells attached using peptide ratios of 0.5 and 1 mg/g alginate, 
ranging from 9.5% of the cells at the lower ratio, to about 44% at the higher ratio. 
Laminin coated gels showed ~60% cell attachment [52].  Due to these previous findings, 
NPCs were also challenged with this substrate.  NPCs were seeded on different constructs 
and migration during a 5 day period was quantified and normalized based on the ratio of 
the radius of migration distance of the cells out of the original colony to the radius of the 
original colony (Fig 4.10).  It was observed that plain alginate constructs (control) as well 
as constructs comprised of alginate chemically modified with the peptide YIGSR 
promoted minimal migration of NPCs, with the average ratio of migration distance to the 
original colony radius being 1.1 ± 0.1 and 1.3 ± 0.1, respectively (p>0.05). . Interestingly 
however, NPCs seeded on YIGSR modified alginate constructs did not show any visible 
differentiation patterns or migration.  This may be due to that the fact that YIGSR acts as 
an optimal peptide fragment for NB2a attachment [52], but is not large enough to 
sufficiently sustain NPC attachment.  However, laminin 111-coated alginate constructs 
and control laminin 111-coated culture dishes promoted more extensive NPC migration 
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(2.5 ± 0.3 and 2.0 ± 0.2 times the distance of the original radius, respectively; p<0.05).  
The incorporation of Fb/BDNF or Fb/NT-3- within the alginate scaffold increased 
migration distance of NPCs to 4.5 ± 0.6 and 9.8 ± 1.9 times the original radius, 
respectively (p<0.001).  The addition of a PLO rate-controlling membrane coat to the 
alginate constructs with encapsulated Fb/BDNF and Fb/NT-3 did not significantly affect 
migration distance (p >0.05).  
 The significance of this finding is that this study has shown that NPCs retain their 
unique ability to migrate and can do so on the surface of the alginate construct.  Current 
studies from literature have shown that direct NPC injection allows for cell migration, but 
reduces the localization of the treatment since there is no guarantee that all injected cells 
will migrate and integrate into the specified areas.  Stem cells that do not migrate towards 
the injured areas and differentiate have the potential to cause harmful side effects [95].  In 
general the transplantation of undifferentiated stem cells poses the risk of tumor 
formation in vivo [95, 96].  However, the developed alginate construct has been shown to 
promote differentiation and migration on the surface of the construct.   Hence, the 
construct has the ability to reduce the risk associated with undifferentiated stem cells, 
while allowing for their regenerative potential.   
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4.3.6 Expression of Neurotrophic Factor Receptors 
 
 The studies conducted suggest that the NPCs are indeed receptive to the 
neurotrophic factors secreted by the encapsulated fibroblasts. To further demonstrate this, 
the expression of neurotrophic receptors on the NPCs was visualized and quantified.  
BDNF and NT-3 have the ability to bind to a high affinity receptor Trk B and Trk C 
respectively.  Additionally they can both bind to p75, a low affinity receptor [97].  
Staining for p75 showed that 79.5 ± 2.1% of NPCs stained for the p75 receptor (Fig 4.11 
A).  The presence of  this receptor proves that the released BDNF and NT-3 have a 
potential way of binding to the NPCs.  67.2 ± 3.6% of NPCs cells stained for TrkB (high 
affinity receptor for BDNF) and 65.8 ± 1.9% for TrkC  (high affinity receptor for NT-3) 
receptors (Fig 4.11 B & C).  Hence, it can be concluded that most NPCs express at least 
one neurotrophic factor receptor, either high or low affinity, allowing for the cells to be 
responsive to the neurotrophic factors released by the encapsulated fibroblasts [97].   
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Figure 15. Expression of Neurotrophic Factor Receptors on Neural Progenitor  
 Fluorescence micrographs showing the expression of neurotrophic factor receptors on 
NPCs seeded on laminin 111 coated alginate discs after 1 day in culture stained with the 
following antibodies: anti-p75 (A) anti-Trk B (B), and anti-Trk C (C), scale bar = 
100µm. 
 
 
A. B. 
C. 
Figure 4.11: Expression of Neurotrophic Factor Receptors on NPCs 
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4.4 NPC Differentiation on Alginate Constructs 
4.4.1 Multi-lineage Differentiation of NPCs on Alginate Constructs 
 
 Because NPCs normally have a multi-lineage differentiation potential restricted to 
neuronal cells (neurons, oligodendrocytes, and astrocytes), an immunohistochemical 
analysis was performed to elucidate the phenotypes of the cells differentiated from NPCs 
on alginate constructs.  After 7 days in culture, cells derived from NPCs seeded on 
alginate constructs with or without encapsulated neurotrophic factor-producing 
fibroblasts were immunoreactive with antibodies against ßIII-tubulin, GalC, and GFAP 
(Table 3.1) indicating that the alginate constructs allowed NPCs to differentiate into all 
three distinct cell lineages (Fig 4.12).  This provides the fundamental knowledge that the 
constructs do not change the phenotypical fate of the NPCs from strictly neuronal 
lineages.  Hence, alginate constructs seeded with NPCs can be used for the purpose of 
repairing CNS tissue since all three distinct lineages are present in the differentiated cells.   
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Figure 16. Multi-Lineage Differentiation of NPCs on Alginate Constructs 
Fluorescence micrographs showing multi-lineage differentiation of NPCs on laminin 
111 and PLO coated alginate discs with or without encapsulated Fb/NT-3 or 
Fb/BDNF.  After 5 days in culture, cells were stained with the following antibodies: 
anti-β-tubulin (red), anti-GALc (green), and anti-GFAP (blue), scale bar = 100µm. . 
 
Figure 4.12: Multi-Lineage Differentiation of NPCs on Alginate Constructs 
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4.4.2 Differentiation Profiles of NPCs on Alginate Constructs 
 
 Once NPCs had attached, they were allowed to differentiate and migrate for 7 
days.  It was observed that NPCs exhibited different patterns of cell morphology and 
migration when seeded on the three different alginate constructs or grown on a plain 
laminin 111-coated culture dishes (Fig 4.13 ).  NPCs seeded in the laminin 111-coated 
culture dishes retained their NPC morphology as reported in literature  (Fig 4.13 A) [98-
100]. Cells seeded on laminin 111- and PLO-coated alginate constructs without any 
encapsulated fibroblasts, kept their spherical form and migrated with an even distribution 
around the original colony (Fig 4.13 B).  However, cells seeded on laminin 111 and PLO-
coated alginate constructs with encapsulated Fb/BDNF lost their round shape and formed 
into oval spheroids while migrating out in a curved pattern (Fig 4.13 C).  NPCs seeded on 
laminin 111- and PLO-coated alginate constructs with Fb/NT-3 kept their round shape 
while differentiated cells did not migrate out in an even area, but rather projected 
outwards as straight fasculations (Fig. 4.13 D).   This observation combined with the fact 
that the NPCs have receptors for neurotrophic factors and can increase migration with the 
addition of neurotrophic factors, led to the possibility of encouraging different lineage 
phenotypes of NPCs on different constructs.   
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Figure 17. Differentiation Profiles of NPCs on Alginate Constructs 
Light micrographs showing multi-lineage differentiation of NPCs on laminin 111 
coated culture dish (A) laminin 11 and PLO coated alginate construct (B), laminin 
111 and PLO coated alginate construct with encapsulated Fb/BDNF (C) and 
Fb/NT-3 (D) scale bar = 100µm. 
A. B. 
C. D. 
Figure 4.13: Differentiation Profiles of NPCs on Alginate Constructs 
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4.4.3 Directed Lineage Differentiation  
 
 After NPCs had been seeded, attached, and had differentiated on alginate 
constructs, their actual phenotypical morphology was studied and quantified in order to 
adequately assess the biological effect of the constructs on the cells.  To quantify the 
differentiation of NPCs on the different alginate constructs, the percentage of cells that 
were positively differentiated into neurons (ßIII-tubulin, MAP-2), oligodendrocytes 
(GalC, CNPase), and astrocytes (GFAP, S100b) were determined through 
immunohistochemical staining (Fig 4.14).  Of the NPCs seeded in culture dishes and on 
alginate constructs without encapsulated fibroblasts 62.5 ± 4.5% and 53.0 ± 5.1% were 
GFAP positive, respectively (p<0.01). Additionally, 69.9 ± 4.1% of the NPCs seeded in 
laminin-111 coated cultured dishes and 49.2 ± 4.4% of the cells seeded on plain laminin-
111 coated alginate constructs were S100b positive.  Both were markers for astrocytic 
differentiation.  The differentiation patterns for both these cases were significantly 
different in that the plain laminin 111 coated alginate constructs showed a significantly 
lower astrocyte production and different percentages of cells differentiated towards each 
lineage (p<0.01).  The alginate construct itself seemed to be reducing astrocytic 
differentiation and promoting a neuronal and oligodendrocyte lineage phenotype.  The 
reason for this could possibly be that the alginate construct acts as a favorable substrate 
for neuronal differentiation by providing a mechanically stable substrate that ensures 
viability of the cells. 
 However, 53.1 ± 9.1% (GalC positive) of the cells seeded on alginate constructs 
with encapsulated Fb/BDNF and 54.9 ± 8.0% (CNPase positive) of the cells exhibited an 
oligodendrocyte phenotype.  Conversely, only 35.0 ± 5.4% and 29.3 ± 7.2% of the cells 
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seeded on alginate constructs with Fb/NT-3 expressed GalC and CNPase respectively, 
whereas 52.7 ± 4.7% (βIII-tubulin positive) and 55.9 ± 6.5% (MAP-2 positive) of the 
cells had differentiated into neurons.  Both types of constructs with encapsulated 
fibroblasts showed a significantly lower astrocyte production [12.3 ± 3.3% (GFAP 
positive); 17.1 ± 4.5% (S100b positive) for Fb/BDNF and 10.79 ± 5.9% (GFAP positive); 
14.7 ± 2.9% (S100b positive) for Fb/NT-3] as compared to those cells seeded in culture 
dishes or on cell-free alginate constructs (p<0.01).  Additionally, there was no statistical 
significance between different markers for the same lineage for each case tested (p>0.05).  
Hence, lineage directed differentiation of NPCs is clearly evident through choice of the 
alginate construct employed.  
 Various ECM substrates for NPC growth, as well as cell free administration of 
neurotrophic factors on NPCs in culture have been reported to show a potential for 
directing neural differentiation [97, 101-105].  Silva et al. have recently shown rapid 
differentiation into neurons with 35% of total cells staining positive for βΙΙΙ-tubulin 
inside self assembling nanotubes composed of IKVAV-containing peptide ampiphiles 
[87]. Interestingly, the alginate constructs developed in this thesis were able to direct the 
differentiation of NPCs by greater amounts than in other studies while at the same time 
greatly increase NPC migration.  Alginate constructs with encapsulated neurotrophic 
factor-producing fibroblasts greatly reduced the number of cells that exhibit an astrocyte 
phenotype.  Selective differentiation of NPCs was possible on these constructs in that 
cells seeded on constructs with encapsulated Fb/BDNF exhibited an oligodendrocyte 
phenotype, while those seeded on constructs with NT-3-producing fibroblasts acquired a 
neuronal phenotype.  The significance of these findings suggest that these directed 
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lineage differentiation patterns might also be influenced by the physical, mechanical, and 
chemical properties of the alginate construct itself.  The alginate construct itself promotes 
neuronal differentiation by providing a favorable substrate on which these cells can grow, 
thereby reducing astrocyte formation.   Moreover, the alginate constructs were shown to 
induce terminal differentiation of NPCs, hence reducing the risks of undifferentiated cells 
and tumor formation.   Since normal differentiation profiles require a large amount of 
astrocytes as the framework for neurons to grow and survive, the alginate construct itself 
may have properties equivalent to this.   
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4.4.4 Encapsulation of NPCs within Alginate Constructs 
 
 Once the behavior of NPCs on the surface of the alginate constructs was 
sufficiently observed and evaluated, NPCs were then encapsulated within the construct to 
compare our results with those for encapsulation in alginate described in literature.  Since 
studies from literature have concentrated on encapsulating NPCs for delivery to injury 
sites [63, 86], the differentiation of NPCs was studied through this method.  After 7 days 
post encapsulation within the alginate construct, NPCs showed significantly lower 
migration as compared to those on the surface (ratio of migration distance to original 
size: 1.3 ± 0.1; p <0.001) when cultured with NPC differentiation medium and the 
migration of the NPCs was quantified (Fig 4.15 & 4.16).  Visual observations showed a 
small ring of migrated cells around the NPC colony and very little cellular process 
extensions.  NPCs seeded on the surface of the laminin 111 coated alginate construct 
however showed normal differentiation patterns, migration (Ratio of migration distance: 
2.9 ± 0.2), and cellular process extensions.  Additionally NPCs encapsulated within the 
construct and cultured with NPC proliferation medium failed to form large spheres as 
compared to those NPCs in culture.  The significance of this finding shows that the 
alginate construct acts as a favorable substrate for migration and differentiation for those 
NPCs growing on the surface, but effectively hinders normal NPC processes when they 
are encapsulated within the construct..  
 Although Ashton et al.  found that encapsulating an alginate lyase enzyme along 
with the NPCs in alginate capsules allowed for cell proliferation and increased cell 
density through a gradual degradation of the alginate capsule, the enzyme’s effect on 
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NPC differentiation was not studied. Hence, it is unknown how NPCs encapsulated in the 
manner will behave when differentiated in vitro and more importantly, in vivo. Hence, 
encapsulation of the NPCs within alginate cannot be sufficiently accepted as a viable 
strategy for immediate NPC delivery for regenerative medicine.   
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Figure 20. Quantification of Migration Distance of Different Delivery Strategies  
Graph representing the quantification of NPC migration on the surface and 
encapsulated in alginate constructs after 5 days in culture (n=10). *(p<0.001) 
 
Figure 4.16: Quantification of Migration Distance of Different Delivery 
Strategies of NPCs 
Delivery Strategy 
* 
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4.5 In vivo Studies 
4.5.1 Alginate Construct Transplantation in Healthy Mouse Brain 
 
 To assess the tissue response of implanting the constructs in vivo, alginate 
constructs with and without encapsulated Fb/BDNF-producing fibroblasts were 
transplanted into the cranial cavity of mice, directly apposed to the cerebral cortex.  After 
7 days, the intact constructs were retrieved and fibroblasts were visualized.  It was 
determined that the fibroblasts were still producing BDNF, as assessed by positive β-
galactosidase expression (Fig. 4.17).  Additionally, at the site of implantation, there was 
not any detectable evidence of cell death (TUNEL positive cells), suggesting that the 
construct was not toxic to brain tissue in the course of implantation (Fig 4.18) and did not 
cause any collateral damage. This is consistent with other reports in literature [65, 106, 
107]. Moreover, elevated levels of BDNF immunoreactivity were detected in the cortical 
tissue adjacent to the alginate constructs containing encapsulated Fb/BDNF which were 
transplanted in the mice, but not on the contralateral side of the same mice, or in mice 
with a sham operation or a transplanted fibroblast-free alginate construct (Fig 4.19).  This 
suggests that that the alginate constructs successfully deliver BDNF to the tissue adjacent 
to where they are implanted.  This significant finding further illustrates the localized 
delivery of neurotrophic factors to the actual site of implantation.   
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4.5.2 Implantation of Fb/BDNF Alginate Constructs After Simulated Brain Injury 
 
 After tissue compatibility and in vivo BDNF delivery capacity of the alginate 
constructs was assessed, the constructs containing encapsulated Fb/BDNF were 
transplanted into the cranial cavity of mice which had received a simulated brain injury.  
Here it was observed that the Fb/BDNF alginate construct reduced the number of 
damaged cells (TUNEL positive) as compared to those with an injury and sham implant 
after 4 days. (Fig 4.20 & 4.21).  The percentage of damaged cells for brain injury model 
mice with a transplanted alginate construct with encapsulated Fb/BDNF was significantly 
lower than those with a brain injury and a sham implant (damaged cells after implantation 
of Fb/BDNF construct: 2.2 ± 1.0%, Sham: 8.1 ± 2.8%; p<0.01). Even fibroblast free 
alginate constructs significantly reduced the number of damaged cells as compared to a 
sham (damaged cells after implantation of fibroblast free alginate construct: 6.4 ± 0.9%; 
Sham: 8.1 ± 2.8%; p<0.05).  The alginate construct itself seems to have regenerative 
properties and can aid in the reduction of damage due to injury.  These results suggest 
that these alginate constructs can be successfully transplanted in vivo, where they deliver 
BDNF to the adjacent brain tissue and help to reduce the severity of the sustained injury 
as judged by cell mortality.  Additionally, this was consistent with what had been seen 
when alginate microcapsules containing encapsulated Fb/BDNF were implanted at the 
site of spinal cord injury [50, 65].  Since BDNF has been previously and currently shown 
to reduce the severity of cell damage in injured CNS tissue, this construct acts as an 
effective way of delivering this trophic factor.  Additionally, the use of alginate as a 
carrier for these trophic factors seems to facilitate regeneration through its physical, 
chemical, and mechanical properties.  Alginate has been proven to reduce scar formation 
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in the CNS injuries [67, 68] and this may be the main reason that using it as a delivery 
vehicle for trophic factors, or any other type of regenerative therapy, may help in 
reduction of the severity of injury and eventual regeneration of damaged tissue. 
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4.5.3 Implantation of Alginate Constructs Seeded With NPCs After Simulated    
         Brain Injury 
 
 To further elucidate the effectiveness and design of the multi-functional construct 
for repair after a brain injury, alginate constructs seeded with fluorescently labeled (DiI) 
NPCs on the surface were implanted at the site of injury.  The effectiveness of these 
constructs to promote migration of the NPCs into the injury area as well as the ability to 
influence phenotypical differentiation was evaluated in comparison to free NPCs injected 
without a construct.  
4.5.4 Migration of NPCs into Brain Injury Area 
 
 In order to adequately assess the delivery of NPCs to the site of injury, alginate 
constructs with and without encapsulated Fb/BDNF and seeded with DiI labeled NPCs 
were transplanted into the cranial cavity of mice with a simulated brain injury.   The 
migration of NPCs into the injured brain matter was then visualized after 4 days.  As 
expected, NPCs injected into the injury site without being seeded on alginate constructs 
showed migration of cells into the injury area [53, 108-110].  DiI labeled NPCs were 
clearly visible throughout the entire injury area (Fig 4.22).  Hence, in order to determine 
the effectiveness of the alginate construct as a delivery vehicle for these NPCs, the 
migration of cells into the injury area from the surface of the construct was visualized as 
well.  After 4 days post implantation of alginate constructs (with and without 
encapsulated Fb/BDNF) in the injured mouse brain, NPCs that were originally seeded on 
the surface of the constructs had migrated off the construct and spread throughout the 
injury area (Fig 4.23 & 4.24).  Additionally, both types of alginate constructs showed this 
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same visual pattern of NPC migration as compared to NPCs injected alone.  When 
observed visually, all experimental groups showed that the majority of NPCs had 
migrated into the injury interface with a few cells migrating up to 200 µm into the brain 
tissue.  This was consistent with literature where it had been shown that NPC migration 
was possible through direct injection of cells [53, 108-110].  However, these alginate 
constructs provided similar migration patterns with fewer of the risks, since the cells were 
in a differentiated state.  Hence, the implantation of alginate constructs seeded with NPCs 
is a feasible method for delivery of these cells to the injury area.  
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4.5.5 Phenotypical Staining of Migrated NPCs in Brain Tissue 
 
 Since NPCs migration from the surface of the construct into the injury area in a 
simulated brain injury model had been visualized in this study, the actual phenotypes of 
the migrated NPCs were then studied through an immunohistochemical staining of the 
brain sections. Reports from literature have stated that the injury environment needs to be 
manipulated in order to ensure proper delivery on NPCs and stem cells [53, 111, 112]. 
Specifically, Wu et al. reported on the fact that neural stem cells migrate and integrate 
into tissue when injected with an implanted alginate sponge.  However, due to the 
inhibitory environment of the injury the majority of these transplanted cells take on an 
astrocytic phenotype [53].  Hence, it may be possible that the transplanted cells may be 
contributing to glial scar formation.  Additionally, Cao et al. found that pluripotent stem 
cells become glial cells when implanted in CNS models due to the same inhibitory cues 
[111].  Further studies have focused on developing restricted precursor cells for 
implantation in an effort to reduce glial cell formation of undifferentiated cells.  
However, it was found that neural restricted precursor cells (NRPs) can not differentiate 
and survive sufficiently enough to manipulate the injury environment in a CNS 
injury[112].  Hence, the ability of the aforementioned alginate construct to allow for 
integration of lineage restricted cells was studied.   
 As an experimental test of the construct, 3 mice were injected with NPCs 
suspended in differentiation medium, while 6 mice had alginate constructs seeded with 
DiI labeled NPCs (with and without encapsulated Fb/BDNF) implanted at their brain 
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injury site.  The phenotypical lineages of the transplanted NPCs were then visualized 
after 4 days.   Immunostaining for GFAP (astrocytic marker) in the brain samples 
containing free NPCs in differentiation medium (without alginate construct), NPCs on a 
plain alginate construct, and NPCs on the alginate construct with encapsulated Fb/BDNF  
(Fig 4.25) showed a smaller population of donor NPCs (DiI labeled) positive for GFAP 
in the latter condition than in the former two conditions.  In general, samples treated with 
free NPCs injected without an alginate construct and NPCs seeded on a plain alginate 
construct exhibited larger populations of astrocytes in the injury area when compared to 
the brain samples treated with the NPCs on alginate constructs with encapsulated 
Fb/BDNF.  Many studies in literature have shown that astrocytes have been correlated 
with the formation of an inhibitory glial scar [33, 53, 67].  Therefore, a reduction in 
astrocyte ingrowth following brain injury is believed to be highly desirable.  Although the 
exact mechanism by which the alginate construct may reduce astrocyte formation in vivo 
is unknown, the construct seems to direct lineages of NPCs as previously observed in the 
in vitro studies.  As expected, the alginate construct with encapsulated Fb/BDNF directed 
lineages away from an astrocytic phenotype (Fig 4.25).  Hence, it can be assumed that the 
alginate constructs have the ability to influence the injury environment in a brain injury 
model after 4 days.   
 To further elucidate the effect of implanting the developed alginate construct in a 
brain injury model, immunostaining for NeuN (neuronal nucleus marker) was performed 
on all three previously described experimental conditions (Fig 4.26). NPCs in 
differentiation medium, NPCs on a plain alginate construct, and NPCs on an alginate 
construct with encapsulated Fb/BDNF all exhibited positive staining for NeuN.  
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However, fluorescent microscopy and labeling of donor NPCs (DiI labeled) when 
injected without an alginate construct and those transplanted on the plain alginate 
construct, showed that they were not positive for NeuN.  This suggests that neurons seen 
in the samples were of host origin and not from the transplanted cells.  Conversely, 
labeling of samples having been treated with NPCs on an alginate construct with 
encapsulated Fb/BDNF exhibited positive staining of NeuN for the donor NPCs that were 
DiI labeled.  Hence, it seems that the alginate construct with encapsulated Fb/BDNF is 
allowing for differentiation of donor NPCs towards a neuronal lineage.  Once again, the 
mechanisms for this in vivo behavior are unclear, but the construct seems to follow the 
lineage cues as previously described in the in vitro studies.  This further solidifies the fact 
that the alginate constructs can influence the injury environment after 4 days and the 
construct can provide the injury area with neuronal cells while reducing astrocytic 
formation in a brain injury model.   
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4.5.6 Implantation of Alginate Constructs Seeded With NPCs After Spinal Cord    
        Transection 
 
 Given the aforementioned positive results after implanting the multi-functional 
construct in a brain injury model, alginate constructs seeded with fluorescently labeled 
(DiI) NPCs on the surface were implanted after a spinal cord transection.  Since there is a 
greater inflammatory response and ultimately the production of an unfavorable 
environment as a result to injury in the spinal cord injury as opposed to the brain [115], a 
study was done to further understand the constructs’ role in influencing the injury 
environment after a spinal cord injury.  Once again, the effectiveness of these constructs 
to promote migration of the NPCs into the injury area as well as the ability to influence 
phenotypical differentiation was evaluated in comparison to free NPCs injected without a 
construct.  
4.5.7 Migration of NPCs into Spinal Cord Tissue 
 
 Since it had been previously shown that NPCs were able to migrate into the brain 
injury tissue, the behavior of NPCs delivered through the alginate constructs was 
assessed in a spinal cord injury.  The migration of NPCs into the transected spinal cord 
was visualized after 6 days.  As expected, NPCs injected into the injury site without 
being seeded on alginate constructs showed migration of cells into the injury area.  DiI 
labeled NPCs were clearly visible throughout the injured area (Fig 4.27). Six days post 
implantation of alginate constructs (with and without encapsulated Fb/BDNF) in the 
transected rat spinal cord, NPCs that were originally seeded on the surface of the 
constructs had migrated off the construct and spread throughout the injury area. Both 
types of alginate constructs showed this visual pattern of NPC migration as compared to 
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NPCs injected alone (Fig 4.28 & 4.29).  When observed visually, all experimental groups 
showed that the majority of NPCs had migrated into the injury interface with a few cells 
migrating up to 500 µm into the spinal cord tissue.  Hence, the implantation of alginate 
constructs seeded with NPCs is a feasible method for delivery of these cells to a spinal 
cord injury model. 
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4.5.8 Phenotypical Staining of Migrated NPCs in Spinal Cord Tissue 
 
 Since it had been visualized that NPCs had migrated into the injury area of the 
transected spinal cord, the actual phenotypes of the migrated NPCs were then studied 
through an immunohistochemical staining of the spinal cord sections. As previously 
stated, reports from literature have stated that the injury environment needs to be 
manipulated in order to ensure proper delivery on NPCs and stem cells [53, 111, 112].  
Additionally, NPCs transplanted in a spinal cord injury model had previously been shown 
to induce astrocytic differentiation and ultimately contribute to the glial scar [53,111].  
Since our previous findings in a brain injury model had been contrary to this, the effect of 
these constructs on NPC differentiation in a spinal cord injury model were observed and 
quantified.  Visual observations of immunostaining for GFAP (astrocytic marker) in 
the transected spinal cord samples containing free NPCs in differentiation medium 
(without alginate construct), NPCs on a plain alginate construct, and NPCs on the 
alginate construct with encapsulated Fb/BDNF  (Fig 4.30) showed samples treated with 
free NPCs injected without an alginate construct and NPCs seeded on a plain alginate 
construct exhibited larger populations of astrocytes in the injury area when compared to 
the transected spinal cord sections treated with the NPCs on alginate constructs with 
encapsulated Fb/BDNF.  Furthermore, alginate constructs with encapsulated Fb/BDNF 
showed a smaller population of donor NPCs (DiI labeled) positive for GFAP. These 
results seemed to confirm the general trends towards reduced astrocyte formation as seen 
in our previous study with alginate construct implantation in a brain injury model.  More 
specifically, a quantification of positive staining (Fig 4.32) showed that NPCs 
transplanted alone showed 81.8 ± 8.1% of these transplanted cells had differentiated into 
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astrocytes (GFAP positive).  This seemed to be similar to NPCs seeded on a plain 
alginate construct and implanted at the site of spinal cord injury (% GFAP positive: 83.7 
± 7.6%, p>0.05).  However, NPCs seeded on alginate constructs with encapsulated 
Fb/BDNF showed that 32.6 ± 4.9 % of these migrated cells had differentiated into 
astrocytes (p<0.001).  Therefore the astrocytic differentiation had been significantly 
reduced when these alginate constructs with encapsulated Fb/BDNF were implanted.   
 To further elucidate the effect of implanting the developed alginate construct in a 
spinal cord injury model, immunostaining for NeuN (neuronal nucleus marker) was 
performed on all three previously described experimental conditions (Fig 4.31).  
Fluorescent microscopy and labeling of donor NPCs (DiI labeled) when injected without 
an alginate construct and those transplanted on the plain alginate construct, showed that 
very few cells were positive for NeuN.  Conversely, labeling of samples having been 
treated with NPCs on an alginate construct with encapsulated Fb/BDNF exhibited 
positive staining of NeuN for the donor NPCs that were DiI labeled.  Hence, it seems that 
the alginate construct with encapsulated Fb/BDNF is allowing for differentiation of donor 
NPCs towards a neuronal lineage.  Once again, the findings in this spinal cord injury 
study seemed to follow the same general trends previously reported in the brain injury 
model with an increase in neuronal formation.  More specifically, a quantification of 
positive staining for NeuN (Fig 4.32) showed that NPCs transplanted alone showed 23.3 
± 6.3% of these transplanted cells had differentiated into neurons.  This once again 
seemed to be similar to NPCs seeded on a plain alginate construct and implanted at the 
site of spinal cord injury (% NeuN positive: 25.2 ± 11.2%, p>0.05).  However, NPCs 
seeded on alginate constructs with encapsulated Fb/BDNF showed that 62.5 ± 7.8 % of 
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these migrated cells had differentiated into neurons (p<0.001).  Therefore the 
differentiation into neurons had been significantly increased when these alginate 
constructs with encapsulated Fb/BDNF were implanted.   
 This study further clarifies the fact that it is possible to influence the unfavorable 
environment of a spinal cord injury.  More specifically, cues can be given to the NPCs in 
order to direct their differentiation after implantation for 6 days.  Contrary to previous 
studies in literature, this alginate construct can potentially provide the injury area with 
neuronal cells while reducing astrocytic formation in a spinal cord and brain injury model 
[111].  
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Figure 36. Quantification of Phenotypical Staining of NPCs Migrated into 
Spinal Cord Tissue 
Graphs representing the quantification of donor (DiI labeled ) NPC differentiation 
profiles in spinal cord tissue 6 days post injury (n=30). * (p<0.001) 
 
Figure 4.32:. Quantification of Phenotypical Staining of NPCs Migrated Into 
Spinal Cord Tissue 
* 
* 
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5. Conclusions 
 
 The results of this thesis demonstrate that these multi-functional alginate 
constructs have the ability to deliver neurotrophic factors continuously while at the same 
time enhancing the differentiation capacity of NPCs seeded on their surface.  
Specifically, they promote the attachment, survival, migration and direct the phenotypical 
differentiation of NPCs.   Most importantly the NPCs seeded on alginate constructs seem 
to retain their phenotypical cues delivered in vitro when implanted in the unfavorable 
environment of brain and spinal cord injury models. 
 To date, studies reported in literature have primarily concentrated on showing the 
potential of NPCs for regeneration, proliferation, and lineage differentiation after direct 
implantation of undifferentiated cells into an injury site [53, 90, 109, 113]. Here, we have 
shown that NPCs can be differentiated on the surface of our tailor-made construct prior to 
implantation, are immediately available for integration into the injury site, and are 
localized towards a specific site of injury.  In addition to the regenerative capacity of 
NPCs to replace damaged cells, this construct continuously releases neurotrophic factors 
to further aid in injury recovery.   
 Unlike normal culture conditions, the alginate constructs also showed a high NPC 
viability. This characteristic may be attributed to the fact that the calcium carbonate 
alginate constructs had a favorable pH (7.2-7.4) for NPC growth and/or that the 
constructs contained carbonate ions that acted as buffering agents against toxic cell by-
products.   Additionally, these constructs seemed to favor NPC attachment, as opposed to 
similar biomaterials, while simultaneously increasing the differentiation potential of the 
cells.  The construct also promoted cell contacts, differentiation, and migration. NPCs 
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seeded on laminin 111-coated alginate constructs also showed multi-lineage 
differentiation and migration, a normal characteristic of NPC colonies. Interestingly 
however, NPCs seeded on YIGSR modified alginate constructs did not show any visible 
differentiation patterns or migration.  This may be due to that the fact that YIGSR acts as 
an optimal peptide fragment for NB2a attachment [53], but is not large enough to 
sufficiently sustain NPC attachment.   
 Due to the described attributes, these alginate constructs have the potential for 
regenerative treatment when implanted into injury sites since the viable NPCs are able to 
interact immediately with the surrounding host tissue.  Moreover, this thesis has 
documented the ability to engineer the alginate constructs to increase NPC migration as 
well as direct the NPCs to selectively differentiate into neurons, astrocytes and 
oligodendrocytes.  Therefore, these constructs can act as both neural tissue-engineered 
scaffolds and as neurotrophic factor delivery vehicles which can be implanted at selected 
sites of injury.  Using this delivery system, the choice of cells and growth factors can be 
tailored for different applications. The growth factors chosen for this study, BDNF and 
NT-3, are known to promote neuronal survival and neural repair.  However, a variety of 
other growth or trophic factors can be incorporated by simply encapsulating other 
genetically engineered fibroblasts or controlled delivery devices.  
 Interestingly these alginate constructs were able to direct the differentiation of 
NPCs by greater amounts than in other studies while at the same time greatly increase 
NPC migration.  Alginate constructs with encapsulated neurotrophic factor-producing 
fibroblasts greatly reduced the number of cells that exhibit an astrocyte phenotype.  
Selective differentiation of NPCs was possible on these constructs in that cells seeded on 
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constructs with encapsulated Fb/BDNF exhibited an oligodendrocyte phenotype, while 
those seeded on constructs with NT-3-producing fibroblasts acquired a neuronal 
phenotype.  These directed lineage differentiation patterns might also be influenced by 
the physical, mechanical, and chemical properties of the alginate construct itself.   
Additionally, the alginate construct itself may promote neuronal and oligodendrocyte 
differentiation by providing a favorable substrate on which these cells can grow.   Since 
normal differentiation profiles require a large amount of astrocytes as the framework for 
neurons, the alginate construct itself may have properties equivalent to this.   
 In vivo implantation of the alginate construct in the cranial cavity of mice was 
shown to be viable for 7 days.  This can be attributed to the fact that the construct itself 
did not induce any extra cell death after implantation. These constructs were also shown 
to reduce the amount of damaged cells at the site of injury, making them extremely 
promising candidates for CNS repair.  Additionally alginate constructs seeded with NPCs 
showed similar migration patterns when compared to NPCs injected without any 
construct and implanted at the site of brain and spinal cord injury.  Hence, it can be 
concluded that the alginate construct developed here is a viable strategy for NPC delivery 
to injury sites.  Most importantly, the immunohistochemical analysis of the injury site 
showed that alginate constructs maintained the phenotypical cues given to the NPCs to 
restrict lineages, when implanted at the site of injury.  In comparison to NPCs injected 
alone, those seeded on alginate constructs with encapsulated Fb/BDNF showed a lower 
amount of astrocyte formation and a higher amount of neuronal differentiation.  
Therefore, it can be concluded that the alginate constructs did not contribute to glial scar 
formation while delivering neurons to the injury area. 
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 Overall, the construct that has been created here represents a highly adaptable 
tissue engineering system incorporating ECM, growth factors and cells, which has the 
potential for use in a variety of biomedical applications.   
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6. Recommendations 
 
 This thesis has shown that alginate constructs can influence NPC differentiation 
while reducing the severity of injury through neurotrophic factor release and NPC 
migration.  In order to further optimize the findings presented in this thesis, the 
recommendations for future studies are presented below.   
1. To study the mechanical properties of the alginate constructs and their effect on 
NPC differentiation.  By first studying and then varying the mechanical properties 
of the construct it may be possible to direct differentiation profiles of the NPCs in 
a similar manner to the chemical differentiation as studied here.  Hence, in 
conjunction with the chemical differentiation, via neurotrophic factors, this study 
may provide an optimal method to restrict NPC lineages.   
2. Incorporation of the enzyme chondroitinase ABC into the construct and to study 
its effect on NPC differentiation. This enzyme helps to degrade growth inhibitory 
proteoglycans that are present at the site of injury. Hence, by adding this enzyme 
to the construct, it may be possible to create a more favorable environment for 
NPC differentiation and migration. A release profile would have to be performed 
to study the concentration of enzyme released from the constructs. The effect of 
the enzyme on encapsulated Fb/BDNF cells and NPC differentiation would also 
have to be verified. These would help to determine if the construct could have 
additional factors that could enhance neuronal regeneration at the injury site. 
3. To create geometrical guidance channels for NPC growth and differentiation on 
the surface of the alginate construct.  These channels should be fabricated with the 
ability to guide NPC migration patterns in a later direction.  Hence, it will be 
  
134 
possible to limit and guide the distance that NPCs move and create a more 
favorable construct with guided cell migration for injury recovery.  Design an 
alginate construct with guidance channels and seed the NPCs within them.  
Observe migration patterns to see if NPCs migrate out of the channels.   
4. To study the mechanistic effect of neurotrophic factors and alginate on NPC 
differentiation profiles and lineages. More specifically, design an alginate 
construct and allow for directed differentiation.  The actual molecular and 
mechanistic changes in the NPC would have to be studied in order to determine 
the actual effect of alginate constructs on NPC differentiation through receptors 
and a molecular level study. 
5. Quanitification of BDNF and NT-3 release from alginate constructs.  This can be 
achieved through an ELISA assay to quantitatively assess the amount of 
neurotrophic factor produced and released from the constructs. 
6. The final recommendation would be to do a long term in vivo study in order to 
test the regenerative capabilities of the alginate construct when implanted in an 
injury model. Place the constructs in rat spinal injury models and study the effects 
on neuronal regeneration by performing an immunohistochemical study on some 
animals and behavioral analysis on others. The immunohistochemical study 
would help to determine the type and length of neuronal cells on the construct and 
the behavioral analysis would help to evaluate the limb functions in the paralyzed 
animals.  The long term effect of phenotypical differentiation of donor NPCs can 
be studied as well.   
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Appendix A 
Protocol for Bioconjugating YIGSR to alginate 
 
1.  All glassware should be rinsed first with deionized water and then with alcohol 
and dried. 
2. Alginate (FMC Biopolymer, a high G-content alginate) is dissolved in MES 
buffer (0.1 M MES + 0.3 M NaCl, pH 6.5) to obtain a 1 % (w/v) solution. The 
pH should be no higher than 6.5 since it affects the efficiency of the conjugation 
process using the carbodimide crosslinker. 
3. Once the alginate is dissolved in the DI water 1-ethyl-3-(3-
dimethylaminopropyl) carbodimide (EDC) is added to activate the carboxyl 
groups in alginate. Different molar concentrations of the carboxylic acid groups 
can be activated by varying the concentration of the EDC added. 
4. N-hydroxysulfosuccinimide (sulfo-NHS) is then added at a molar ratio of 1:2 to 
EDC which help to stabilize the intermediate formed between EDC and the 
carboxylic acid groups of alginate. 
5. The activation of the carboxyl acid groups is then allowed to continue for 15 
minutes by continuously stirring the solution. The appropriate concentration of 
either YIGSR is then added. The peptide conjugation process is then allowed to 
proceed for 24 hours by gently stirring the solution since vigorous stirring could 
lead to warming of the alginate solution and in turn hinder the peptide 
conjugation reaction. 
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6. Spectra/Por dialysis tubing is cut into several pieces and soaked in deionized 
water for 2 hours to remove any preservatives like sodium azide and glycerine. 
The water is replaced a few times to ensure complete removal of any 
preservatives from the tubing. 
7. The alginate-peptide conjugate is then transferred to the cut and soaked pieces 
of dialysis of tubes and the tubes are sealed with closures. 
8. The dialysis tubes with the modified alginate are then placed in a tank 
containing large volume of deionized water to remove any unreacted EDC, 
sulfo-NHS or peptide. This dialysis process is then allowed to continue for 4 
days with the water being constantly replaced everyday to ensure complete 
removal of unreacted products. 
9. The dialyzed alginate-peptide conjugate is then transferred to 50ml 
polypropylene centrifuge tubes and placed in a -85ºC freezer till the solution is 
completely frozen. The centrifuge tubes are then placed in a -75ºC freeze dryer 
that has a vacuum of about 20 millitorrs, for about 4 days, which turns the 
alginate peptide conjugate into a dry fibrous form. 
10. The alginate-peptide conjugate is weighed, labeled and then placed in a -20ºC 
freezer for future use. 
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Appendix B 
Protocol for counting cells using a hemocytometer 
 
1. Cells are removed from a culture plate by exposing them to 0.2% trypsin EDTA 
for 3 minutes. The enzyme helps to break the cell adhesion moieties that help 
the cells to adhere to the culture plate. The cells are not exposed to trypsin for 
more than 3 minutes to avoid the enzyme from digesting the cells. 
2. After exposure to trypsin the cells are resuspended in growth medium 
containing fetal bovine serum to neutralize the action of trypsin and also to 
break up any cells that might still be adherent to the culture plate.  
3. The cells suspended in growth medium are then placed in a 15ml centrifuge 
tube. The contents of the centrifuge tube are centrifuged at 1000 RPMs for 5 
minutes. The cell pellet is then resuspended in growth medium to ensure 
complete removal of trypsin. 
4. 20µl of growth medium with the cells suspended in it is placed in a 1.5ml 
microcentrifuge tube. 80µl of 0.4% Trypan blue stain is added to the cell 
suspension. The cells now form 1 in 5 parts of the solution. The solution is then 
transferred to a hemocytometer using a pipette. 
5. A cover slip is placed over the center of the hemocytometer and the cell 
suspension is added using capillary action by placing the tip of the pipette in the 
groove and just under the cover slip. The centre of the hemocytometer has 2 
marked square chambers called Neubar’s chamber. 
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6. The cells in the 4 large corner squares of the chamber, which has 16 small 
squares, are counted. The total count is then divided by 4 to get average cell 
count. Since each small square has a volume of 1µl the average cell count is 
then multiplied by 50,000 to get the total cell count in 1 ml of medium. 
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Appendix C 
Protocol for Cryostat of Tissue Sections 
 
1. The tissue is fixed in 4% PFA overnight and then washed three times with PBS 
(1X).  After sufficient washing, the tissue is placed in 30% sucrose and allowed to 
sink.    
2. Once the tissue has been placed in sucrose, it is embedded and then cut. First, a 
container is filled with dry ice to cool. 
3. Moulds for cutting are then named prior to starting the procedure.  These moulds 
are filled with the frozen section medium (Preferably M1 or OCT). 
4. Place the tissue at the bottom of the mold while keeping the mould in the 
container with dry ice and wait for it to freeze completely (till medium becomes 
white-indicates freezing). 
5. Keep the mould in -80 (overnight preferable- or else 4 hrs minimum if intended 
for use immediately) 
6. Switch on the cryostat and bring temp to about -30. 
7. Cut the tissue and make slices, according to desired thickness  (40 um for brain, 
20 um for spinal cord) and place on gelatin treated microscope slides. 
8. Dry the slide for 2hrs at room temperature (overnight preferable) 
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Appendix D 
Protocol for Immunohistochemistry 
 
1. Slides are taken out of -80oC and allowed to equilibrate to room temperature.  A 
blocking buffer solution of 2% BSA + 0.1% Triton is crated.  This solution is then 
filtered to remove any foreign particulates.   
2. The microscope slides are then hydrated with PBS (1X) for 10 minutes.  
3. Add 1ml/slide of blocking buffer solution and keep it on the slides for 15 -20 
mins at room temperature. 
4. Tap off blocking buffer and add primary antibody to the blocking buffer (1:100 
conc. in blocking buffer) 100 µl/slide  
5. In case of double staining (add 2 µl of each antibody to 200 µl of blocking 
buffer), add 100ul/slide.  
6. After primary antibodies have been added, place the paraffin film on the slide 
(like a cover slip) and keep at 4oC overnight. 
7. The next day, remove the paraffin film and tap the slide to rid the primary 
antibody.  After the primary has been removed, wash with 1X PBS, three times, 
each time waiting for 2-3 minutes. 
8. Tap off the PBS; and add the proper secondary antibody (1: 100 conc. in 1XPBS), 
100 µl /slide . Put on the paraffin films over microscope slides and wait for 45 
minutes to 1 hour at room temperature.  Make sure to keep the samples in dark. 
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9. Tap off the secondary antibody and add the nuclear stain.(DAPI; 1: 500 µl  
concentration in 1XPBS). 
10. Keep DAPI stain on microscope slides for 7 to 10 minutes. 
11. Wash unreacted DAPI off with filtered 1XPBS  three times. 
12. Put 1 drop mounting medium. Put on the coverslip (22 X 55 mm) such that no air 
bubble is formed .use pipette tips to drag out the air bubbles 
13. Wait until it dries well and look under microscope 
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